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Satellite cells are muscle stem cells that reside in a niche between the basal lamina and 
sarcolemma of mature muscle fibers. Upon muscle injury, these cells are activated to 
myoblasts that subsequently proliferate, migrate and differentiate into myotubes in order to 
facilitate repair. Extracellular matrix (ECM) and growth factors are known to regulate certain 
aspects of myogenesis however, a comprehensive study of the direct effects of niche ECM 
factors on C2C12 myogenesis has not previously been conducted and forms the core of this 
study.  
 
We first examined the role of hepatocyte growth factor (HGF) on C2C12 myogenesis. HGF 
is known to initiate activation of quiescent satellite cells in the niche and regulate various 
aspects of differentiation. In this study, we determined that HGF has a dose-dependent dual 
role in C2C12 myogenesis. HGF (2 ng/ml) significantly promoted cell division, but reduced 
myogenic commitment and fusion. Conversely, 10 ng/ml HGF reduced proliferative 
capability, but increased differentiation. This is potentially regulated by changes in c-Met 
expression; analysis revealed significantly decreased c-Met expression in differentiating 
cells cultured with 2 ng/ml HGF, but increased expression in proliferating cells with 10 
ng/ml HGF. Furthermore, investigation into the mechanisms by which HGF affects 
myogenesis, revealed that mitogen-activated protein kinase (MAPKs: ERK, JNK or p38K) 
and phosphatidylinositol-3-kinase (PI3K) inhibition abrogated the HGF-stimulated increase 
in cell number. Interestingly, PI3K and p38 kinase facilitated the negative effect of HGF on 
proliferation, while ERK inhibition abrogated the HGF-mediated decrease in differentiation.  
 
Next, we analyzed the effect of the satellite cell niche ECM on C2C12 myogenesis. Collagen 
IV and laminin, the major components of the basal lamina, bind to and interact with satellite 
cells via integrins and other cell surface proteins such as the tetraspanin, CD9. Matrigel 
significantly increased terminal fusion but had no effect on Pax7+ and MyoD+ cell numbers. 
Collagen IV, the second largest constituent of Matrigel, was observed to significantly 
increase MyoD+ cell numbers and terminal fusion without effecting percentage Pax7+ cell 
numbers. Furthermore collagen IV stimulated an increase in CD9 expression on 
differentiating cells, such that cells cultured on collagen IV required higher levels of 
neutralizing anti-CD9 monoclonal antibodies to reduce fusion. These results indicate, for the 
 ii 
first time, that the interaction of collagen IV with CD9 is a critical mediator of skeletal 
muscle fusion and that the observed pro-myogenic effect is accompanied, on a molecular 
level, by an increase in the number of committed MyoD positive cells.  
 
Extracellular matrix (ECM) and growth factors are known to have complex interactions that 
may modulate their activity in vivo. Lastly, in an attempt to more closely mimic in vivo 
conditions, murine C2C12 myoblasts were cultured on collagen IV in HGF-supplemented 
media followed by assessment of differentiation and proliferation. Collagen IV was not able 
to negate the negative effect of HGF (2 ng/ml) on fusion but was able to restore normal 
MyHC expression. Due to a collagen IV stimulated increase in CD9 expression in 
differentiating myoblasts, cells cultured on collagen IV required higher levels of neutralizing 
anti-CD9 monoclonal antibodies to reduce fusion; an effect not observed when cells were 
differentiated in the presence of HGF alone. HGF (10 ng/ml) treated samples we unable to 
demonstrate any fusion when CD9 was completely blocked suggesting that CD9 is a crucial 
co-factor in HGF (10 ng/ml)-induced fusion. These results show, for the first time, that 
collagen IV is able to modulate certain aspects of the dual role of HGF on myogenesis.  
 
In summary, we identified a novel dose-dependent dual role of HGF in myogenesis and 
uncovered that these effects are mediated by changes in c-Met expression and downstream 
MAPK and PI3K signalling. We showed, for the first time, that collagen IV is able to 
positively mediate C2C12 differentiation via a CD9-dependent pathway. Lastly, we revealed 
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Myofibers (skeletal muscle cells) are post-mitotic and therefore unable to divide and repair 
damaged muscle themselves (Grounds et al., 2002). However, a cellular repair system is 
present in adult muscle in the form of a stem/progenitor cell known as the satellite cell (De 
Bari et al., 2003).  Satellite cells reside in a niche between the basal lamina and plasma 
membrane of the adjacent myofiber (Mauro, 1961, Grefte et al., 2012). They are positioned 
along the entire length of the muscle fiber and ensure the capability of muscle repair 
regardless of the site of injury (Muir et al., 1965). Morphologically, satellite cells are 
fusiform in shape with a small nucleus and reduced organelle content (Charge and Rudnicki, 
2004). 
 
In healthy, uninjured muscle, satellite cells are metabolically inactive, a state known as 
quiescence. Upon muscle damage, they are activated from quiescence by hepatocyte growth 
factor (HGF) and begin to proliferate (Allen et al., 1995). Activated satellite cells, also 
known as myoblasts, migrate along the basal lamina towards the site of injury where they 
differentiate and facilitate tissue repair (Allen et al., 1995). The precise composition of the 
extracellular matrix (ECM) changes as the cell moves from its niche, along the basal lamina 
and into the wound. The two main protein components of the basal lamina are collagen IV 
and laminin (Boonen and Post, 2008). However, upon entering a fibrotic wound, myoblasts 
come into contact with high levels of collagen I, fibronectin and decorin (Vaz et al., 2012). 
Previous research has highlighted the importance of the ECM and growth factors in 
regulating the activation, commitment, migration and differentiation of myoblasts (Borojevic, 
1999, Goetsch et al., 2011, Grefte et al., 2012, Melo et al., 1996, Osses and Brandan, 2002, 
Schenke-Layland et al., 2007, Vaz, 2009) and a comprehensive assessment of the effects of 





1.2 Satellite cell characterization: 
 
Satellite cells were first identified by Mauro (1961) in the hind limb muscles of frogs. 
Research by Muir et al. (1965) identified and further characterized these cells in skeletal 
muscle of mice and fruit bats. Electron microscopy allowed the visualization of mammalian 
satellite cells residing in their niche between the basal lamina and plasma membrane of a 
myofiber (Figure 1.1) (Muir et al., 1965). Although satellite cells were suspected to play a 
role in skeletal muscle repair in 1961, conclusive proof of this was only shown some 17 
years later. Snow (1978), using autoradiography, showed that satellite cells were essential for 
the regeneration of muscle in Sprague-Dawley rats. Here, satellite cells autoradiographically 
labeled with tritiated thymidine were transplanted into non-radioactive littermates. Following 
muscle damage, newly repaired myotubes appeared radioactively labeled thus proving that 
the satellite cells had differentiated into myotubes during fiber repair. In this study, activated 
satellite cells were also shown to be capable of myotube formation in vitro confirming their 
stem cell-like nature (Snow, 1978). 
 
Satellite cells are not the only mononucleated cells found in skeletal muscle tissue (Figure 
1.1). Pericytes are contractile cells that regulate capillary flow to the myofiber. They have 
recently been shown to retain a certain level of plasticity allowing them to differentiate into 
muscle cells and fibroblasts, and are able to assist in skeletal muscle regeneration (Dellavalle 




Figure 1.1: Satellite cell localization. Skeletal muscle is made up of densely packed, parallel myofibers. These 
fibers are multinucleated (containing myonuclei) and are surrounded by pericytes and satellite cells (red arrows 
indicate satellite cells). Blood vessels supply the fiber with nutrients, growth factors and circulating 
inflammatory cells in times of muscle injury. Mesenchymal progenitors and connective tissue cells are also 
found integrated within skeletal muscle tissue (Pannerec et al., 2012).  
 
 
Mesenchymal progenitors are capable of differentiating into a range of cell types, including 
adipocytes and muscle (Uezumi et al., 2010). Within skeletal muscle, they secrete hepatocyte 
growth factor (HGF) which plays a vital role in the activation of satellite cells upon muscle 
injury (Catlow et al., 2003). Connective tissue cells are one of the most abundant cell types 
found embedded in skeletal muscle; they form a sheath of connective tissue around each 
muscle fiber (Rowe, 1981). This not only protects the fiber, but also transfers tension 
between adjacent muscle fibers and supplies a element of elasticity to the muscle bundle 
(Trotter and Purslow, 1992). Unlike myofibers, satellite cells are mononuclear and express 
specific satellite cell proteins such as Pax7 and muscle regulatory factors (MRFs), which 
allow them to be identified in skeletal muscle tissue (Charge and Rudnicki, 2004) 
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1.3 Pax and Myogenic Regulatory Factors (MRFs): 
 
Paired-box (Pax) proteins 3/7 and the myogenic regulatory factors (MRFs) are transcription 
factors specific to muscle cell lineages (Seale et al., 2000). They play distinct, stage-specific 
roles during myogenesis and their use as molecular markers has allowed great insight into 
myogenesis. The expression of these transcription factors at different stages of muscle 
regeneration is outlined in Figure 1.2. 
 
 
Figure 1.2: The progression from quiescent satellite cell to multinucleated myofiber showing the 
expression of transcription factors during this process. Quiescent satellite cells express Pax7 with low levels 
of Myf5. Myoblasts express the transcriptions factors Pax7, MyoD and myogenin. Differentiated myocytes 
down-regulate expression of Pax7, but continue to express MyoD and myogenin. Mature multinucleated muscle 
fibers express transcription factors myogenin and MRF4 as well as the structural protein Myosin Heavy Chain 
(MyHC) (Charge and Rudnicki, 2004, Cornelison and Wold, 1997, Fuchtbauer and Westphal, 1992, Gayraud-
Morel et al., 2007, Le Grand and Rudnicki, 2007, Ustanina et al., 2007, Bentzinger et al., 2012). 
 
 5 
Pax3 is a major regulator of embryonic muscle development, however, its importance in 
postnatal skeletal muscle growth and repair is overshadowed by Pax7 (Young and Wagers, 
2010). Once activated, proliferating myoblasts increase expression of the paired-box 
transcription factor Pax7 (Le Grand and Rudnicki, 2007). Pax7 is known to play a role in the 
self-renewal pathway that is responsible for maintaining the population of satellite cells in 
muscle. Pax7 is expressed in both quiescent and activated satellite cells, but is down-
regulated prior to differentiation (Relaix et al., 2006). After several proliferative cycles, 
myoblasts exit the cell cycle and enter a state of differentiation which allows subsequent 
fusion and myotube formation (Dhawan and Rando, 2005). If Pax7 expression is not 
downregulated, cells do not differentiate, but rather re-enter a quiescent state. 
 
Following down-regulation of Pax7 in differentiating cells, MyoD expression increases, 
suggesting that Pax7 plays a role in self renewal via direct suppression of MyoD expression 
(Olguin and Olwin, 2004). MyoD expression is accompanied by up-regulation of Myf5, 
myogenin and myosin heavy chain (MyHC) expression, before subsequent fusion into 
multinucleated muscle fibers as reflected in Figure 1.2 (Le Grand and Rudnicki, 2007). 
Through various knockout studies it has been shown that MyoD is a crucial regulatory factor 
of post-natal myogenesis with knockouts unable to effectively differentiate satellite cells. 
Triple knockouts of myogenin, MRF4 and Myf5 also show a complete inability to perform 
successful myogenesis (Gayraud-Morel et al., 2007). This indicates that the regulatory 
factors work in unison to ensure successful myogenesis.  
 
Satellite cells express a number of cell surface proteins including M-cadherin, neural cell 
adhesion molecule (N-CAM), c-Met and CD9 (Table 1.1). c-Met and CD9 are of particular 
relevance to this study as HGF signals through c-Met and collagen IV is known to bind to 









Table 1.1: Common satellite cell proteins and their functions. 













Myogenic specification (adult), 
self renewal 
 
(Horst et al., 2006) 
 
(Seale et al., 2000) 
 
MRFs: 




Commitment to differentiation 
 
(Cornelison et al., 2000) 







(Fuchtbauer and Westphal, 
1992) 
(Bentzinger et al., 2012) 







Receptor for HGF 
Role in integrin signaling, fusion 
 
(Cornelison and Wold, 1997) 
(Beauchamp et al., 2000) 
(Tachibana and Hemler, 1999, 








(Bader et al., 1982) 
    
Abbreviations: Q: Quiescent; A: Activated; D: Differentiated; NCAM: neural cell adhesion molecule; Pax3/7: 
paired-box transcription factor 3/7; Myf5: myogenic factor 5; MyHC: myosin heavy chain. 
 
C2C12 cells are an immortalized myoblast line used as a research model for myogenesis 
isolated from C3H mice following a crush injury experiment (Yaffe and Saxel, 1977). Upon 
stimulation to differentiate, C2C12 cells are observed to downregulate Pax7, upregulate 
MyoD and begin differentiation (Zammit et al., 2006b). This is followed by the expression 
of the abovementioned MRFs and followed by fusion into actin and myosin positive 
myotubes (Burattini et al., 2004, Olguin et al., 2007). This pattern of expression of 
transcription factors as differentiation progresses closely mirrors that of primary culture 
myoblast differentiation and in vivo myogenesis (Olguin et al., 2007). This outlines the value 
in quantifying C2C12 transcription factor and MRF levels as a primary step in understanding 




1.4 Skeletal muscle repair: 
 
Adult skeletal muscle is considered an extremely stable tissue type. Schmalbruch and Lewis 
(2000) estimate that approximately 2% of mononuclei are replaced each week in healthy 
adult mice (Schmalbruch and Lewis, 2000). Skeletal muscle also possesses the ability to 
rapidly regenerate following injury.  
 
Muscle tissue repair can be classified into two distinct stages, namely degradation and 
regeneration. Degeneration begins with necrosis and partial or full autolysis of the fiber 
ensues (Schmalbruch and Lewis, 2000). This degradation releases factors which act as 
chemotactic signals to inflammatory cells in the bloodstream. Neutrophils are present at the 
site of injury within 6 hours of injury followed by macrophages approximately 48 hours 
post-injury (Figure 1.3A) (Tidball, 1995). Although fibroblasts are recruited to the site of 
injury, deposition of large amounts of fibrotic scar tissue is not characteristic for these types 
of injuries (Schmalbruch and Lewis, 2000). The released factors from the damaged muscle 
fiber also stimulate activation of the regeneration process. This is characterized by mitotic 
cell division of satellite cells followed by migration into the injury site and later, fusion of 
myoblasts to existing myofibers or to one another forming new myotubes (Figure 1.3B) 
(Schmalbruch and Lewis, 2000). Late in the regeneration stage, remodeling occurs and 
myotubes increase in size due to hypertrophy. Following complete regeneration, repaired 
myofibers are morphologically indistinguishable from undamaged fibers and exhibit 
complete contractile functionality (Figure 1.3C) (Schmalbruch and Lewis, 2000). 
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Figure 1.3: Normal muscle regeneration. Neutrophils and macrophages enter injury site. Activated myoblasts 
differentiate into multinucleated myotubes and fuse to existing myofibers thereby bridging the injury without 
scar tissue formation. Full muscle repair ensues (Constructed from (Jarvinen et al., 2000, Occleston et al., 2010, 
Tidball and Wehling-Henricks, 2007)). 
 
However, in cases of extremely severe or frequent injury (Figure 1.4A), excessive ECM 
deposition by infiltrating fibroblasts may result in the formation of a fibrotic scar (Figure 
1.4B) (Jarvinen et al., 2000). The fibrotic scar, composed of ECM factors including 
fibronectin and collagen III (which is later remodeled to collagen I), prevents myoblasts from 
fusing and bridging the original muscle fiber (Figure 1.4C) (Tidball and Wehling-Henricks, 
2007). This, in turn, results in a loss of contractile ability (Tidball and Wehling-Henricks, 
2007).  This type of scarring also occurs as a result of repetitive injuries characteristic of 
myopathies such as Duchenne muscular dystrophy, where increasing fibrosis causes 
transdifferentiation of myoblasts into fibroblasts (Grounds, 2014). 
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Figure 1.4: Scar tissue formation following repeated or extremely severe muscle injury. Fibroblasts enter 
the site of injury and deposit ECM proteins such as collagen I and fibronectin. Myotubes then attach to either 
side of the fibrotic scar and fuse with the existing muscle fibers. This results in fibrotic scar tissue formation 
and impeded muscle function (Constructed from (Jarvinen et al., 2000, Occleston et al., 2010, Tidball and 
Wehling-Henricks, 2007)). 
 
1.5 Satellite cell niche:  
 
The stem cell niche is defined as the local microenvironment that supports, maintains and 
regulates stem cell identity and function. In particular, the stem cell niche has been shown to 
regulate self-renewal via a mechanism known as asymmetric cell division (Kuang et al., 
2008). Asymmetric cell division is characterized by mitosis resulting in daughter cells of 
different cellular fates (Morrison and Kimble, 2006) as opposed to symmetric cell division 
which results in identical daughter cells. With regard to myogenesis, asymmetric cell 
division results in one daughter cell that will migrate to the site of injury and differentiate, 
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facilitating regeneration. The other daughter cell will return to the niche and re-enter 
quiescence (Kuang et al., 2007). This process is extremely important in maintaining a 
population of satellite cells within the muscle and thus ensuring its regenerative potential. 
 
The satellite cell niche is found along the surface of muscle fibers between the sarcolemma 
and the basal lamina. The satellite cell is in contact with the muscle fiber, components of the 
basal lamina and the vascular system that supplies the niche (Fuchs et al., 2004). The muscle 
fiber has been shown to supply the satellite cell with mechanical, electrical, and chemical 
signals that play a role in the regulation of its function (Pallafacchina et al., 2010). The basal 
lamina surrounding myofibers consists of various ECM components such as laminin-211, 
collagen IV and various proteoglycans such as syndecans, glypican-1, perlecan, decorin and 
biglycan. These factors contribute to maintaining quiescence of the satellite cells while still 
in their niche (Pallafacchina et al., 2010). The vascular system supplies nutrients and oxygen 
to the muscle fiber. This network supplies extrinsic signals from the circulatory system, 
which along with factors released by macrophages and fibroblasts, regulate the quiescence, 
activation and proliferation of satellite cells (Pallafacchina et al., 2010).  
 
Growth and ECM factors of the satellite cell niche and wound (Table 1.2) regulate the 
process of muscle repair and regeneration (Allen et al., 1995, Amento and Beck, 1991, 
Catlow et al., 2003, De Bari et al., 2003, Ewton et al., 1988, Fuchs et al., 2004, Goetsch et 
al., 2011, Grinnell, 1984, Lehto et al., 1985, Lin et al., 2010, Podleski et al., 1979, Schabort 
et al., 2009, Schenke-Layland et al., 2007, Schonherr et al., 1995, Tatsumi et al., 1998, Vaz, 
2009, von der Mark and Ocalan, 1989, Yao et al., 1996). An understanding of how these 
factors affect myogenesis may provide clues as how to improve the restoration of muscle 










Table 1.2: Comparison of components found within the satellite cell niche and those found in a fibrotic 
wound. 
Component Stem cell niche Fibrotic Wound References 
Fibronectin Not expressed Fibronectin (Dourdin et al., 1997) 
Collagens Col IV, VI  Col I, III (Kjaer, 2004, Friedl et 
al., 1998) 
Laminin Laminin 211, 411, 511 Not expressed (Grounds et al., 2005) 
Proteoglycans Biglycan, Syndecans Decorin, Dermatan 
Sulfates 
(Mochida et al., 2009) 
Growth Factors HGF, TGF-β TGF-β (Amento and Beck, 
1991) (Allen et al., 
1995) 
 
1.6 Extracellular matrix and growth factors in the niche and wound:  
 
The extracellular matrix (ECM) surrounding skeletal muscle was initially thought to act 
solely as a scaffold to support and maintain the structure of the tissue, but has since been 
shown to regulate many cellular processes (Grounds et al., 2005). These include cell survival, 
activation, proliferation, migration and differentiation (Friedl and Brocker, 2000). A vast 
array of proteins, proteoglycans and polysaccharides form the lattice-like meshwork of the 
ECM (Wu et al., 2005). Individual components of the ECM such as laminin, fibronectin, 
collagen I, tenacin and decorin have been shown to influence stem cell activation, migration 
and differentiation in various tissues (Lin et al., 2010, Schenke-Layland et al., 2007, Friedl 
and Brocker, 2000, Wehrle-Haller and Chiquet, 1993). Growth factors control many aspects 
of myogenesis including activation, proliferation, migration, differentiation and fusion of 
myoblasts into myotubes. In this respect, important growth factor families include the 
hepatocyte growth factor (HGF) family, the fibroblast growth factor (FGF) family and the 
transforming growth factor beta (TFG-β) family.  
 
1.6.1 Fibronectin: Fibronectin has been shown to be crucial in embryogenesis with 
fibronectin knockout mice rarely developing beyond day 11 of embryogenesis (George et al., 
1993). This is due to the vital role that fibronectin plays in guiding the migration of various 
cell types during early embryogenesis (Darribere and Schwarzbauer, 2000).  Fibronectin, in 
its insoluble form, is a glycoprotein that forms fibrils as components of the ECM. This 
protein exists in two other forms: cell surface fibronectin oligomers and a soluble dimeric 
form located in the blood (Grinnell, 1984). The insoluble form of fibronectin has been shown 
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to be able to bind various ECM components including collagen and tenacin (Hocking et al., 
2008). Along with tenacin, fibronectin is among the first ECM factors to be produced by 
fibroblasts in severely injured muscle tissue (Grinnell, 1984). Fibronectin forms multimeric 
cross-linked structures with fibrin which act as a scaffold for invading inflammatory cells 
and myoblasts (Dourdin et al., 1997). Fibronectin has been shown to improve the myogenic 
differentiation of C2C12 cells in vitro (Table 1.3) (Garcia et al., 1999, Lin et al., 2010). 
Garcia et al (1999) showed that blocking with monoclonal antibodies against fibronectin 
itself, or the integrin with which it interacts (α5β1), abrogates the observed increase in 
C2C12 differentiation. 
 
1.6.2 Collagens: Collagens are a family of structural proteins known to perform 
numerous functions in vivo. Fibrillar collagens include collagen I, II, III, IV, V, VI and XI 
and are all composed of three polypeptide α-chains which arrange into a triple helix (Ricard-
Blum and Ruggiero, 2005). The basal lamina has been shown to be rich in collagen IV, 
which forms the basic scaffold into which laminin networks are integrated (Timpl and 
Brown, 1996). Collagen IV binds to cell surface receptors knows as integrins as well as 
tetraspanins (Leitinger and Hohenester, 2007). Integrins are the major transmembrane 
receptors involved in cell adhesion to the ECM (Humphries et al., 2006).  
 
Although little is known regarding the effect of collagen IV on myoblast differentiation, 
collagen IV is known to interact with the CD9 receptor (Castro-Sanchez et al., 2010). This 
cell surface glycoprotein is expressed on the surface of C2C12 cells and has been shown to 
be vital in the normal development of skeletal muscle. CD9 expression is upregulated in the 
early stages of C2C12 differentiation and blocking CD9 using monoclonal antibodies 
substantially inhibits and delays conversion of C2C12 cells to elongated myotubes 
(Tachibana and Hemler, 1999, Charrin et al., 2013). This suggests that collagen IV may 
positively regulate myogenesis via CD9. Knockout studies have shown that collagen IV is 
not essential for early embryo development, but is essential for the correct structural 
assembly of various basement membranes during late development (Poschl et al., 2004). At 
day 10.5 to 11.5 lethality occurs in collagen IV null mice due to structural abnormalities in 
the basement membrane between parietal endoderm cells and trophoblast cells known as the 
Reichert’s membrane. Collagen IV has been shown to increase the differentiation of human 
and mouse embryonic stem cell types into mesodermal cell lineages including hematopoietic, 
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endothelial, and smooth muscle cells (Table 1.3) (Ali et al., 1998, Schenke-Layland et al., 
2007, Taru Sharma et al., 2012).  
 
Collagen I is the most abundant collagen subtype within mammalian tissues and is the final 
product of collagen remodeling during scar tissue formation (Ricard-Blum and Ruggiero, 
2005). TGF-β promotes fibrosis by stimulating collagen I deposition by fibroblasts following 
severe muscle injury (Tidball and Wehling-Henricks, 2007). Additionally, the interstitial 
ECM surrounding skeletal muscle fibers has been shown to be rich in collagen I, which 
increases integrin α1β1 expression on fibroblasts (Kjaer, 2004). Increased expression of 
integrin α1β1 causes the clumping of fibroblasts on collagen fibers via a critical GFOGER 
(O denotes hydroxyproline) motif within the collagen’s I domain (Emsley et al., 2000). 
Collagen I also binds to discoidin domain receptor 1 and 2 (DDR1 and DDR2) (Leitinger 
and Hohenester, 2007). DDRs are receptor tyrosine kinases (RTKs) involved in the 
regulation of cell growth, differentiation and metabolism (Mohan et al., 2001). Collagen I 
has been shown to inhibit the differentiation of rat primary culture satellite cells (Table 1.3) 
(Kjaer, 2004, Grefte et al., 2012).  
 
1.6.3 Laminins: Laminins, composed of multiple heterodimers consisting of α, β and 
γ polypeptide chains, are a major protein component of the basal lamina. They are key bridge 
molecules, connecting the myofiber to the basal lamina; their absence results in congenital 
muscle dystrophies (Grounds et al., 2005). These conditions arise as, without the connection 
of the myofiber to the basal lamina, the contractile force generated by the myofiber cannot be 
transferred effectively to the interstitial connective tissue (Grounds et al., 2005). Laminin-
211, found around the sarcolemma of muscle fibers, binds to collagen IV in the basal lamina 
(Grounds et al., 2005). Laminin-111 and laminin-211 (merosin) differ in their alpha domains, 
however laminin-111 has been shown to improve the repair of skeletal muscle in merosin 
deficient mice (Van Ry et al., 2013). This suggests a similar functional nature of these two 
isoforms. Although the effect of laminin deficiency is well documented in congenital 
muscular dystrophies, its effect on myoblast differentiation remains a topic for debate. 
Laminin-111 has been shown by some to increase C2C12 differentiation (Grossi et al., 2007) 
while others have found that laminin had no effect on C2C12 differentiation (Vaz, 2009) 
(Table 1.3).  
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1.6.4 Decorin: Decorin, a proteoglycan, is composed of a leucine-rich core protein 
containing 12 subunits with each subunit containing a 24 amino acid polypeptide (Mochida 
et al., 2009). Decorin plays a vital role in collagen fibrillogenesis by binding to collagen and 
causing a delay in fibril assembly. This results in the reduction of the fibril diameter and 
ensures correct fibril assembly (Mochida et al., 2009). Irregular collagen contours and a 
loosely packed collagen network are the result of decorin scarcity during myogenesis 
(Mochida et al., 2009). Goetsch et al., 2011 found that decorin increases collagen I-
stimulated, but not fibronectin-stimulated migration of mouse myoblasts. Riquelme et al. 
(2001) found that by minimizing the expression of decorin using antisense mRNA, they 
enhanced terminal differentiation of C2C12 cells (Table 1.3). In contrast, recent studies have 
shown decorin to aid in the differentiation of C2C12 cells (Table 1.3) through the 
suppression of myostatin activity (Kishioka et al., 2008). Li et al (2007) showed that decorin 
inhibits transforming growth factor TGF-β1 and can reduce the formation of fibrous scar 
tissue in vivo. This resulted in improved muscle healing after injury using decorin gene 
transfer (Li et al., 2007). The knockout of decorin expression performed by Riquelme et al. 
(2001) may possibly have activated a compensatory mechanism that is responsible for their 
observed improvement in C2C12 terminal differentiation. The findings of Li et al (2007) 
were observed using an animal model as opposed to the C2C12 in vitro model used in the 
two other studies mentioned. These differences in the models used may contribute to the 
observed contrasting results. 
 
 1.6.5 Matrigel: Matrigel, as it is known by its trade name, is an exogenous mixture of 
mainly collagen IV, laminin-111 and various proteoglycans (Hughes et al., 2010). These 
components closely mimic the ECM of the satellite cell niche, providing a valuable tool in 
the study of niche ECM factors. Matrigel is commonly utilized to improve the proliferative 
and myogenic potential of primary isolated myoblasts (Grefte et al., 2012). Grefte et al 
showed that Matrigel did indeed improve the fusion of C2C12 cells in vitro.  Melo et al. 
(1996) demonstrated that the ECM is essential for skeletal muscle differentiation by 
culturing C2C12 myoblasts in the presence or absence of Matrigel. Cells plated in the 
absence of Matrigel were unable to form myotubes by day 3 while those differentiated on 
Matrigel had fused at this time point. Interestingly, when cells were plated in the absence of 
Matrigel, the production of the differentiation-stage specific transcription factor myogenin 
was not prevented, however later muscle-specific gene products such as MyHC were not 
produced by day 3 of differentiation (Melo et al., 1996, Osses and Brandan, 2002). This is 
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compelling evidence that the components of Matrigel speed up C2C12 terminal 
differentiation. 
Table 1.3: The known effects of various ECM and growth factors on stem cell differentiation. 
Component [Concentration] Effect on 
Differentiation 
Cell type References 
Collagen I [1.2 mg/ml] ê Rat primary muscle 
culture 
(Grefte et al., 2012) 
Collagen IV [10 µg/ml] é Various embryonic 
stem cell types, 
neural progenitors  
(Schenke-Layland et al., 
2007, Taru Sharma et al., 
2012, Ali et al., 1998) 
Fibronectin [10 µg/ml,         
5 µg/ml] 
é C2C12 myoblasts, 
Human mesenchymal 
multipotent stem cells 
(Garcia et al., 1999, Lin 
et al., 2010) 
Laminin [10 µg/ml] 
 
[5 µg/ml] 
é   
 
No effect          
C2C12, rat primary 
muscle culture 
(Lin et al., 2010, Grossi 
et al., 2007, Vaz, 2009, 
















(Kishioka et al., 2008) 
 
 
(Riquelme et al., 2001) 
 
(Li et al., 2007) 
HGF Overexpressing 
transfected cells 
ê C2, Mouse primary 
muscle culture 
(Yamane et al., 2004, 











Rat primary culture 
C2C12 myoblasts 
In vivo mouse 
(Grefte et al., 2012) 
(Schabort et al., 2009) 
 
(Armand et al., 2006) 
 
 
1.6.6 HGF: Hepatocyte growth factor (HGF) exists in two forms, pro-HGF and mature HGF. 
Pro-HGF is secreted by mesenchymal cells as a single chain and remains bound in the ECM 
in an inactive form. Upon muscle injury, it is cleaved and activated by a serine protease 
(Catlow et al., 2003). Mature (active) HGF is dimeric and exists as a heavy α-chain (69 kDa) 
and light β-chain (34 kDa) heterodimer. This growth factor is known to play a role in 
development and regeneration of a range of tissues including the endothelium, kidney, lung 
and skeletal muscle (Nakamura and Mizuno, 2010). HGF has been shown to impede the 
differentiation of embryonic mouse tongue cells and increase the proliferation and migration 
of C2C12 myoblasts in vitro (Yamane et al., 2004, Barbero et al., 2001). With regards to 
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skeletal muscle, HGF is of vital importance in the initial stages of muscle regeneration 
(Matsumoto and Nakamura, 1997). 
 
 1.6.6.1 Stability: 
In vivo studies investigating the effect of HGF on liver regeneration have shown that HGF 
has a blood half-life of approximately 3 minutes (Appasamy et al., 1993, Ido et al., 2004, 
Xue et al., 2003). This is mainly due to HGF uptake by the liver and does not suggest that 
HGF is inherently unstable (Appasamy et al., 1993). In fact, two studies have demonstrated 
that HGF is stable at a range of temperatures, pH’s and ionic strengths (Nayeri et al., 2002, 
Nayeri et al., 2004). HGF has however been observed to degrade significantly over a 3 hour 
period when placed in culture flow environments. However, HGF levels remained at over 
90% 3 hours post addition to static media at 37 °C and 5% CO2 (Meneghello et al., 2014).  
 
 1.6.6.2 c-Met receptor: 
The c-Met receptor is a high affinity receptor for HGF. It exists as a 190 kDa transmembrane 
protein composed of an α-chain (50 kDa) and a β-chain (140 kDa) (Tam et al., 2000). Upon 
binding of HGF to the c-Met receptor, Met kinase becomes active (Bottaro et al., 1991). This 
results in 2 tyrosine residues (Tyr1349 and Tyr1356) in the carboxy-terminal tail becoming 
phosphorylated (Figure 1.5). These residues become docking sites for a range of adaptor 
proteins including phosphatidylinositol-3-kinase (PI3K), Grb2-associated adaptor protein 
(Gab1) and growth factor receptor-bound protein 2  (Grb2) (Figure 1.5). These pathways 
proceed to mediate Met-dependent cell proliferation, migration, survival and differentiation 
(Faria et al., 2011). These effects will be further discussed in section 1.6.6.3. Blocking the 
binding of HGF to the c-Met receptor has been shown to prevent the activation of quiescent 
satellite cells in a crush muscle extract experiment, thus confirming the importance of this 
receptor in satellite cell activation (Tatsumi et al., 1998). 
 
Regulation of HGF signalling via c-Met can be achieved by a number of mechanisms. Firstly, 
HGF has been observed to be rapidly internalized and degraded in cells such as hepatocytes, 
and the density of the HGF:c-Met complex on the cell surface is observed to decrease within 
30 minutes of exposure to elevated HGF levels (Naka et al., 1993). c-Met also has a negative 
regulatory site, a tyrosine residue in its juxtamembrane domain which acts by recruiting the 
E3 ubiquitin-protein ligase, casitas B-lineage lymphoma (c-CBL) (Organ and Tsao, 2011). 
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This causes c-Met to be ubiquitinated and thus targeted for proteasome degradation. HGF 
signaling is also regulated by the ability of c-Met to bind a number of protein tyrosine 
phosphatases (PTPs). These phosphatases can control HGF signaling by modifying the 
kinase or binding domains of c-Met (Organ and Tsao, 2011). Lastly, phospholipase Cγ 
(PLCγ) can bind to c-Met and activate protein kinase C (PKC) which acts as a negative 
regulator of c-Met activity (Organ and Tsao, 2011).  
 
 1.6.6.3 Intracellular signaling:  
Growth factor receptor-bound protein 2 (Grb2) and Grb2-associated adaptor protein (Gab1) 
transduce signals through mitogen-activated protein kinases (MAPKs) such as extracellular 
signal-regulated kinases (Erk1 and Erk2), Jun amino-terminal kinases (JNK1, JNK2 and 
JNK3) and p38 (Figure 1.5).  These kinases promote cell proliferation and mediate cell 
migration while signaling through PI3K mediates cell survival and resistance to apoptosis in 
a wide range of cell types (Faria et al., 2011). Proliferation rates are also regulated via 
signalling through SHP2, a tyrosine phosphatase that mediates MAPK activity downstream 
of Grb2 (Li et al., 2009). 
 
The PI3K pathway signals through Akt and has been shown to be important in proliferation, 
differentiation and survival of muscle stem cells (Ceci et al., 2004, Guttridge, 2004). Akt has 
been observed to be vital in the IGF induced increase of myogenin expression in C2C12 cells 
(Xu and Wu, 2000). Inhibition of this pathway by LY294002 a potent, reversible inhibitor of 
phosphoinositide 3-kinases (PI3K), (Maira et al., 2009)(Maira et al., 2009) has been shown 
to interfere with myotube formation and the expression of muscle-specific proteins such as 
MyoD and MyHC (Jiang et al., 1999). 
 
Activation of the ERK pathway by myostatin has been shown to negatively regulate 
myogenesis in C2C12 cells, and this effect can be reversed with the addition of PD98059, a 
potent, selective inhibitor of ERK kinase (Figure 1.5) (Yang et al., 2006). 
 
Activation of the p38 pathway by 5 mM creatine has been shown to increase C2C12 fusion 
and MyHC expression in vitro (Deldicque et al., 2007). Inhibition of p38 by SB205380, a 
highly specific inhibitor of p38 MAPK, has been shown to inhibit sarcomeric myosin 
expression in human embryonal rhabdomyosarcoma cells, indicating a pivotal role for p38 
during myogenesis (Mauro et al., 2002). Inhibition using both PD98059 and SB205380 
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allowed Kook et al., (2008) to determine that mechanical stretch-induced C2C12 
proliferation was not due to an ERK related mechanism but solely due to p38. They also 
showed that 3 uM SB205380 prevented myogenin expression, suggesting that ERK 
activation was essential for efficient C2C12 differentiation. However, inhibition of p38 
increased MyoD expression and myotube formation suggesting that a downregulation of 
activity of this kinase is necessary for myogenesis (Kook et al., 2008).  
 
Activation of jun N-terminal kinase (JNK) has been shown to induce growth arrest and 
differentiation in human embryonal rhabdomyosarcoma cells (Mauro et al., 2002). JNK has 
been suggested to play a role in the inhibition of myogenesis of in L6 and C2 myoblasts via 
the cytoplasmic redistribution of Myf5 (Figure 1.5) (Tam et al., 2000). Inhibition with 
SP600125, a highly specific and potent reversible inhibitor of JNK, has been shown to 
reduce the proliferative potential of primary culture mouse myoblasts (Shi et al., 2013). 
 
Figure 1.5: Schematic representation of c-Met activated signalling in response to HGF. 
 
1.6.7 TGF-β: The transforming growth factor beta (TFG-β) superfamily of proteins 
consists of more than 40 members and includes TGF-β isoforms, bone morphogenetic 
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proteins (BMPs) and growth differentiation factors (GDFs) (Gumienny and Padgett, 2002). 
This group of proteins regulates numerous cellular processes such as growth, cell-cycle 
progression, apoptosis, and differentiation (Vilar et al., 2006). TGF-β2 has been observed to 
suppress myogenic differentiation in the C2 myoblast cell line (Ewton et al., 1988), as well 
as promote proliferation and inhibit myogenic differentiation in the C2C12 myoblast cell line 
(Schabort et al., 2009). However, addition of TGF-β2 to primary myofiber cultures has 
resulted in a reduction of satellite cell numbers indicating the suppression of satellite cell 
proliferation in their natural niche (Bischoff, 1990). Much of the study of the TGF-βs and 
myoblast differentiation has shifted towards myostatin, a potent inhibitor of myogenesis 
(McCroskery et al., 2003).  
 
1.6.8 FGF: Fibroblast growth factor was first identified by its ability to significantly 
promote the proliferation of 3T3 fibroblasts (Armelin, 1973). FGF binds to a tyrosine kinase 
FGF receptor on the surface of cells (Montero et al., 2001). FGF (5 ng/ml) was observed to 
increase the expression of differentiation-specific markers in C2 cells while 25 ng/ml 
induced a reduction in these markers and resulted in impaired cell fusion (Pizette et al., 
1996). FGF has been shown to be important in myogenesis and wound healing (Barrientos et 
al., 2008). Satellite cells express the abovementioned tyrosine kinase FGF receptors, which 
suggests that FGF may play a role in skeletal muscle myogenesis (Armand et al., 2006). 
Indeed, when recombinant FGF is injected into the muscle of injured mice, accelerated 
muscle repair is observed (Armand et al., 2006). These results would suggest a key role for 
FGF in myogenesis, however its specific effect on the myogenic pathway is relatively 
unknown. Interactions between ECM factors and FGF have not yet been examined and may 
yield results that are more aligned with in vivo conditions. 
 
Growth factors are therefore of vital importance in development, maintenance and repair of 
skeletal muscle. They have been shown to interact with specific protein components of the 
ECM and therefore their in vitro combination with ECM factors should more closely mimic 






1.7 Extracellular matrix – growth factor interactions: 
 
The study of the effect of extracellular matrix proteins on the behavior of cells has primarily 
been carried out using culture dishes coated with single ECM components. This approach 
has yielded many insightful results and we are beginning the understand the role of single 
ECM components and growth factors in modulating stem cell behavior (Ali et al., 1998, 
Goetsch et al., 2011, Grefte et al., 2012, Grinnell, 1984, Kishioka et al., 2008, Lin et al., 
2010, Podleski et al., 1979, Schenke-Layland et al., 2007, Yao et al., 1996). However, ECM 
components are known to have complex interactions with each other and with growth factors 
and these interactions are integral to the influence that the ECM and growth factors have in 
vivo (Poschl et al., 2004, Schonherr et al., 1995). 
 
ECM combination assays attempt to more closely simulate in vivo conditions by allowing 
these de novo ECM interactions to take place. Combined ECM experiments often show 
synergistic effects of the individual ECM components. For instance, fibronectin and laminin 
have each been shown to increase the differentiation of adult neural stem/progenitor cells 
and their combination enhanced this increase (Cooke et al., 2010). Decorin has also been 
shown to modulate the positive effect that collagen I has on C2C12 migration, but was 
unable to modulate fibronectin-stimulated migration (Goetsch et al., 2011). In vivo studies 
have shown that, in combination with Matrigel, HGF delays C2C12 myotube formation 
when transplanted into nude mice (Barbero et al., 2001). These studies emphasize the 
importance of investigating ECM interactions and not simply single factors in isolation. 
 
There are various mechanisms by which ECM-growth factor interactions can modulate cell 
behavior. The ECM can directly bind a growth factor, resulting in the sequestration of the 
growth factor and prevention of its presentation to its receptor; a mechanism or negative 
regulation (Hynes, 2009). This type of binding can also protect the growth factor from 
degradation and thus acts as a type of growth factor reservoir. In addition, direct binding can 
also facilitate successful presentation of the growth factor to its receptor. An example of this 
type of binding occurs when FGF-2 binds to heparan sulfate (Schultz and Wysocki, 2009). 
Crystal structure analysis revealed that heparan sulfate binds both FGF-2 and its receptor, 
facilitating subsequent signaling (Schlessinger et al., 2000). It has been suggested that in 
addition to this, heparan sulfate also assists in the dimerization of two FGF receptor 
molecules, an important early step in receptor activation (Wilgus, 2012). Integrin-ECM 
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interactions can also lead to growth factor receptor activation, facilitating an indirect 
interaction between the ECM and growth factors. An example of this type of activation is 
when αVβ3 integrin, expressed on endothelial cells, binds to the glycoprotein vitronectin. 
This binding and integrin signaling enhances cellular responsiveness to Vascular Endothelial 
Growth Factor (VEGF) and can result in activation of VEGF receptor 2 (Wilgus, 2012). 
 
Reversible binding of HGF to immobilized collagen IV has been reported and resulted in a 
collagen-HGF complex that was able to induce primary hepatocyte proliferation in a dose-
dependent manner. Further investigation revealed that binding was due to specific peptide 
sequences unique to collagenous proteins suggesting a specific role for collagens in HGF 
bioavailability and activity (Schuppan et al., 1998). However, very little is known about the 
effect of collagen IV in mediating HGF signaling in myoblasts. 
 
The clinical significance of growth factor-ECM interactions has been suggested in the 
treatment of chronic wounds. Growth factor therapy is a promising technology, however, 
challenges with dosage regulation has suggested that an effective delivery system is lacking 
(Briquez et al., 2015). Due to the recently realized importance of the ECM in regulating the 
bioavailability and presentation of growth factors, ECM-inspired delivery systems in the 
form of biodegradable ECM bandages, have been suggested for growth factor therapies. An 
example of such a system involves a biomatrix constructed with heparan sulfate-mimetic 
molecules to sequester heparan-binding growth factors such as FGF-2 (Liu et al., 2007). In 
other studies, growth factor binding sites were identified in a range of ECM factors including 
collagens, fibronectin and vitronectin (Schuppan et al., 1998, Martino and Hubbell, 2010, 
Upton et al., 2008). The binding sites identified on fibronectin were described as “highly 
promiscuous” and bound to a wide range of growth factors including insulin-like growth 
factor binding-protein-3, FGF-2 and VEGF with a high affinity (Martino and Hubbell, 2010). 
Vitronectin was observed to bind IGF and EGF and this complex was observed to accelerate 
wound healing in non-healing ulcers in a human pilot study (Upton et al., 2008). 
 
1.8 3D skeletal muscle generation: 
 
Future applications of 3D tissue generation technique may involve transplantation of 
engineered tissue to patients with muscle damage. One method to construct three-
dimensional skeletal muscle involves the seeding of myoblasts onto a biodegradable scaffold 
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(Huang et al., 2004). The scaffolds used in the successful generation of 3D muscle by Huang 
et al. (2004) resembled sponge and were made up of 50% poly-L-lactic acid and 50% 
polylactic-glycolic acid. The cells attach and grow on the scaffolds to create functional three-
dimensional skeletal tissue (Levenberg et al., 2005).  
 
An early obstacle encountered in the first three-dimensional skeletal muscle models is that 
they were unable to outgrow the limitations of diffusion (Levenberg et al., 2005). In vivo 
muscle development relies on a vascular system to nourish the tissue; this is absent in 
traditional in vitro muscle cultures (Levenberg et al., 2005). However, in 2005, a team of 
researchers created vascularized skeletal muscle in vitro. The team co-incubated myoblasts, 
embryonic fibroblasts and endothelial cells on a scaffold similar to those described earlier 
and observed the de novo formation of simple vascularized muscle tissue (Levenberg et al., 
2005). This development will allow larger muscle to be grown and take researchers one step 
closer to both accurate models for muscle regeneration as well as autologous muscle 
transplants. 
 
The second method of producing 3D tissues, including muscle, is using 3D bioprinters. This 
method may involve either printing a suitable scaffold from a biodegradable material or 
ECM component or by printing cells directly into a supportive gelatinous matrix, cell by cell, 
in progressive 3D layers (Jakab et al., 2010). Once the basic shape of the tissue is achieved, 
the cells are stimulated to terminally differentiate (Norotte et al., 2009). This technique, 
although in its infancy, is rapidly evolving with the advancement in cell and printer 
technology. Tissue generation using 3D bioprinters offers many important advantages to the 
abovementioned scaffold-seed method. There is a far greater degree of control: 3D 
bioprinting allows high-resolution control of cell distribution, density and even the precise 
placement of different cell types (Ventola, 2014). This control could be an extremely 
valuable tool in overcoming the abovementioned challenge to creating vascularized tissues, 
which will be essential if the in vitro production of complex organs is to be realized (Norotte 
et al., 2009). 
 
Research cited in this chapter outlines the ability of the ECM to influence myoblast behavior. 
The use of biologically relevant substrates and growth factor supplements may aid in the 
development of in vitro functional 3D muscle tissue.  
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1.9 Summary, objectives and aims: 
 
In summary, extracellular matrix and growth factors are known to regulate many aspects of 
cell behavior including myogenesis. ECM factors physically interact with growth factors and 
may modify their action and bioavailability in vivo. By examining the influence that ECM 
factors have on growth factor-mediated satellite cell differentiation, we may be able to better 
understand muscle regeneration and the processes that impair or promote it.  
 
The objective of this study was therefore to understand how the extracellular matrix of the 
satellite cell niche regulates the function of HGF in myogenesis. 
 
 
To address this objective we aimed to: 
 
First establish a baseline by investigating: 
A) The effect of HGF on myogenesis. 
B) The effect of collagen IV on myogenesis. 
 
 Second, determined how the ECM regulates the effect of HGF by investigating: 

















DOSE-DEPENDENT MODULATION OF MYOGENESIS BY HGF: 




Hepatocyte growth factor (HGF) regulates satellite cell activation, proliferation and 
differentiation. We analysed the dose-dependent effects of HGF on myogenesis.  
Murine C2C12 myoblasts were treated with 0, 2 or 10 ng/ml HGF followed by 
assessment of proliferation and differentiation. HGF (2 ng/ml) significantly promoted 
cell division, but reduced myogenic commitment and fusion. Conversely, 10 ng/ml HGF 
reduced proliferative capability, but increased differentiation. c-Met expression 
analysis revealed significantly decreased expression in differentiating cells cultured with 
2 ng/ml HGF, but increased expression in proliferating cells incubated with 10 ng/ml 
HGF. Mitogen-activated protein kinase (MAPKs: ERK, JNK or p38K) and 
phosphatidylinositol-3-kinase (PI3K) inhibition abrogated the HGF-stimulated increase 
in cell number. Interestingly, PI3K and p38 kinase facilitated the negative effect of 
HGF on proliferation, while ERK inhibition abrogated the HGF-mediated decrease in 
differentiation. Dose-dependent effects of HGF are mediated by changes in c-Met 
expression and downstream MAPK and PI3K signalling. 
 
 
Includes data from: 
WALKER, N., KAHAMBA, T., WOUDBERG, N., GOETSCH, K. & NIESLER, C. 2015. 
Dose-dependent modulation of myogenesis by HGF: implications for c-Met expression and 











During skeletal muscle regeneration, the activation of satellite cells, their subsequent 
expansion and the terminal differentiation of the myoblast population is regulated by growth 
factors, such as fibroblast growth factor (FGF), insulin growth factor-1 (IGF-1), transforming 
growth factor beta (TGF-β) and hepatocyte growth factor (HGF) (Gal-Levi et al., 1998, 
O'Reilly et al., 2008, Yamada et al., 2010, O'Blenes et al., 2010, Miller et al., 2000, Pownall 
and Isaacs, 2010). HGF, a heparin-binding protein, is sequestered in an inactive form in the 
extracellular matrix (ECM) of uninjured muscle fibers (Miller et al., 2000); however, upon 
tissue injury it is cleaved and released to stimulate satellite cell activation (Birchmeier and 
Gherardi, 1998). HGF transduces its effects on satellite cells through specific interaction 
with the c-Met receptor (Humphrey et al., 1995). c-Met is a transmembrane tyrosine kinase 
cell surface receptor consisting of a 145 kDa and 50 kDa β- and α-chain (Sonnenberg et al., 
1993). It has been shown to be essential during satellite cell activation, proliferation, 
migration and differentiation (Organ and Tsao, 2011).  
 
Upon binding of HGF to the c-Met receptor, the kinase becomes active (Bottaro et al., 1991). 
This results in the phosphorylation of two tyrosine residues (Tyr1349 and Tyr1356) in the 
carboxy-terminal tail of c-Met (Figure 1.5). The phosphorylated residues become docking 
sites for a range of adaptor proteins including phosphatidylinositol-3-kinase (PI3K), Grb2-
associated adaptor protein (Gab1) and growth factor receptor-bound protein 2  (Grb2). These 
pathways proceed to mediate c-Met-dependent cell proliferation, migration, survival and 
differentiation (Faria et al., 2011). Grb2 and Gab transduce signals through mitogen-
activated protein kinases (MAPKs) such as extracellular signal-regulated kinases (ERK1 and 
ERK2), Jun amino-terminal kinases (JNK1, JNK2 and JNK3) and p38.  It has also been 
shown that HGF regulates proliferation rates via signalling through SHP2, a protein tyrosine 
phosphatase that mediates MAPK activity; these proliferation rates were dependent on the 
HGF dose utilized (Li et al., 2009, Chazaud, 2010).  MAPKs are thought to be more 
intensively involved in regulating cell proliferation, differentiation and cell migration, while 
signaling through PI3K mediates cell survival and resistance to apoptosis (Faria et al., 2011, 
Lluis et al., 2006, Li et al., 2000, Knight and Kothary, 2011, Keren et al., 2005, Organ and 
Tsao, 2011).  
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Regulation of HGF:c-Met signaling can be achieved by a number of mechanisms. In 
hepatocytes, HGF-bound c-Met receptors are internalized and the c-Met cell surface 
concentration is observed to decrease within 30 minutes of exposure to elevated HGF levels 
(Naka et al., 1993). HGF is subsequently degraded and released by the cell. HGF signaling is 
also regulated by a number of protein tyrosine phosphatases (PTPs), which bind to the 
cytoplasmic domain of c-Met. These phosphatases can control HGF signaling by modifying 
the intracellular kinase activity or binding domains of c-Met (Organ & Tsao 2011). Receptor 
protein tyrosine phosphatase beta (RPTP-β) dephosphorylates Tyr1356, while leukocyte 
common antigen-related molecule (LAR) counteracts Met auto-phosphorylation, which 
inhibits MAPK and PI3K activity. Similarly, CD148 prevents binding of signal transducers 
Gab1 and p120 catenin (Baldanzi and Graziani, 2014). Lastly, phospholipase Cγ (PLCγ) can 
bind to the carboxy-terminal tail of c-Met and activate protein kinase C (PKC), which acts as 
a negative regulator of c-Met activity (Organ and Tsao, 2011). 
 
In vitro, it has been demonstrated that HGF activates rat primary culture satellite cells at 
concentrations as low as 2.5 ng/ml (Tatsumi et al., 1998).  Further studies in primary rat 
skeletal myoblasts and the C2C12 murine cell line have also demonstrated a promotion of 
proliferation in response to HGF at concentrations ranging from 3 ng/ml to 50 ng/ml 
(Anastasi et al., 1997, O'Blenes et al., 2010, Allen et al., 1995). In contrast however, a 
separate study utilising rat satellite cells demonstrated a suppression of proliferation in 
response to HGF at concentrations greater than 10 ng/ml (Yamada et al., 2010). A reduction 
in activation and proliferation was also observed in both chicken skeletal muscle and mouse 
C2 cells in response to addition of exogenous HGF at 20 and 50 ng/ml (Gal-Levi et al., 
1998). These conflicting results suggest potential dose-dependent sensitivity regarding the 
effect of HGF on cellular proliferation.  
 
Skeletal myogenesis is regulated by several myogenic regulatory factors (MRFs) including 
MyoD, Myf-5, MRF-4 and myogenin (Gal-Levi et al., 1998, Halevy and Cantley, 2004). 
MRFs are proteins expressed in cells committed to differentiate; together with Pax7, they are 
implicated in specification of the myogenic lineage (McFarlane et al., 2008, Buckingham et 
al., 2006, Seale et al., 2004). Differentiation studies published to date suggest an inhibitory 
effect of HGF (2.5 – 50 ng/ml) on myoblast differentiation (Gal-Levi et al., 1998, Halevy et 
al., 2004, Zeng et al., 2002, Leshem et al., 2000, Yamane et al., 2004). Accumulating 
evidence implies that HGF may influence myogenesis via its regulation of MyoD, Myf-5 and 
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myogenin (Charge and Rudnicki, 2004, Halevy et al., 2004, Rosen et al., 1990). In addition, 
some studies provide evidence of a role for p27 (a cyclin-dependent kinase) and Twist (a 
basic helix-loop-helix transcription factor) in the mediation of HGF on differentiation 
(Leshem et al., 2000).   
 
HGF therefore plays a central role during skeletal muscle myogenesis; however the effect of 
different doses on cellular activities is unclear and requires further examination. In the 
present study we culture the C2C12 murine cell line to examine the effects of different HGF 
concentrations on proliferation and differentiation. Furthermore, we investigate whether 
dose-dependent sensitivities are related to changes in the total protein expression of the c-
Met receptor and utilise both MAPK and PI3K inhibitors in an attempt to understand the 























2.2 Materials and methods 
 
2.2.1 Cell culture 
 
The C2C12 murine cell line was donated by Prof Anna-Mart Engelbrecht (Department of 
Physiological Sciences, University of Stellenbosch, South Africa). Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (Highveld Biological, CN3193-9) supplemented with 
10% (v/v) Fetal Bovine Serum (Biowest, S181H-500), 2% (v/v) L-glutamine (Lonza, BE17-
605E) and 2% (v/v) Penicillin-Streptomycin (Lonza, DE17-602E). For differentiation studies, 
cells were cultured to a confluence of 70% after which media was changed to differentiation 
media (DMEM supplemented with 2% (v/v) horse serum) (Biowest, S090H-100).  
 
2.2.2 HGF addition 
 
Human HGF (PeproTech, cat.100-39) was used at a final concentration range of 0, 2 and 10 
ng/ml and media changed every 48 hours during differentiation studies. Cells were incubated 
at 37°C in a humidified incubator at 5% CO2. All experiments were carried out under sterile 
conditions in a Class II Biohazard Safety Cabinet. Clustal W alignments were conducted to 
compare the amino acid sequences of HGF used in this study and those found in mice (Mus 




PI3K Inhibitor (LY294002, final concentration: 2.5 µM, Santa Cruz, SC-201426), ERK 
inhibitor (PD98059, final concentration: 12.5 µM, Santa Cruz, SC-3532), p38 inhibitor 
(SB205380, final concentration: 5 µM, Santa Cruz, SC-3533) and JNK inhibitor (SP600125, 
final concentration: 5 µM, Santa Cruz, SC-200635) were reconstituted in DMSO (Sigma, 
D2650). Inhibitors were added to growth or differentiation media and replenished every 48 
hours with media change. Final DMSO concentrations never exceeded 0.04% and were not 
found to be toxic to C2C12 cells (Appendix I, Supplementary Figure 1); this is in agreement 
with previous studies where DMSO was shown to be non-toxic in C2C12 cells at 
concentrations up to 0.1% (Moorwood et al., 2011). 
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2.2.4 Cell counts 
 
The cell counts were carried out as previously described (Taylor et al., 2001).  Briefly, 
C2C12 cells were seeded in T25 tissue culture flasks (100 000 cells) containing growth 
media and incubated at 37oC (5% CO2) for 24 hours. HGF (0, 2, 10 ng/ml) was then added 
and cells incubated for a further 24 hours. Thereafter, cells were trypsinized and counted 
using the automated BioRad TC-20 Cell Counter; viability was also assessed using 10 µl 




Cells were differentiated to day 5 in the presence or absence of HGF (0, 2 or 10 ng/ml), fixed 
in 4% paraformaldehyde containing 0.1% Triton X-100 (Sigma, T9284) for 20 minutes and 
blocked with 5% donkey serum for 1 hour. For Myosin Heavy Chain (MyHC) detection, 
coverslips were incubated with a mouse monoclonal MF20 primary antibody 
(Developmental Studies Hybridoma Bank; dilution 1/200) overnight at 4°C. This was 
followed by 4 x 5 minute PBS wash steps prior to incubation with secondary antibody for 1 
hour at room temperature. The secondary antibody was DyLight 594-conjugated AffiniPure 
donkey anti-mouse lgG secondary antibodies (Jackson ImmunoResearch, CN-715-485-151, 
1/1000 dilution). Hoechst (Sigma, B2267; 10 mg/ml stock; 1/2000 dilution) was added to all 
the cells for detection of nuclei. Moviol was used as mounting agent. All images were 
captured using the Zeiss 710 LSM confocal microscope.  
 
2.2.6 Fusion Index 
 
The fusion index was calculated as described previously (Micheli et al., 2011). Briefly, 
myoblasts were differentiated on coverslips in the presence or absence of HGF (2 ng/ml or 
10 ng/ml) and fixed at day 5. Immunocytochemistry was carried out to detect the expression 
of MyHC in the differentiating cells. Five random fields of view of cells were captured using 
the Zeiss 710 LSM confocal microscope. ImageJ software was utilized to determine 
formation of myotubes. The fusion index was calculated as the number of nuclei within 
MyHC-labeled myotubes (two or more nuclei per myotube) divided by the total number of 
nuclei per field of view, multiplied by 100.  
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2.2.7 Western Blotting 
 
Myoblasts were cultured in either growth or differentiation media in the presence or absence 
of HGF (2 ng/ml or 10 ng/ml). Proliferating cells were harvested at day 0 (in growth media 
for 24 hours), while differentiating cells were harvested at days 1, 2 and 5 of differentiation. 
During differentiation, media (supplemented with or without HGF) was changed every 2 
days. Cell lysates were prepared in 100 µl RIPA buffer (Sigma-Aldrich, R0278) containing 1 
µl Protease Inhibitor Cocktail (PIC) (Sigma-Aldrich, P8340) for 1 hour on ice, followed by 
centrifugation at 12 000 rpm for 5 minutes. Lysates were sonicated using the Ultrasonic 
cleaner (Shalam Laboratory Suppliers) and protein concentrations determined via the 
Bradford Assay (Bradford, 1976). Total protein (30 µg) was loaded onto 12.5% SDS Poly-
acrylamide gel, and following separation, was transferred onto a Nitrocellulose membrane 
(Life Sciences, P/N 66485) using Western Blotting. The membrane was then incubated with 
primary antibodies overnight. Primary antibody dilutions: rabbit anti-c-Met 1:500 
(Invitrogen, 182257); mouse anti-alpha-tubulin 1:1000 (Santa Cruz Biotechnology B-7, sc-
5286); and mouse anti-MyHC 1:1000 (Developmental Hybridoma Bank, MF20-S). 
Secondary antibody dilutions: goat anti-rabbit (Dako PO448) 1:12000 for c-Met detection; 
rabbit anti-mouse (Dako PO260) 1:12000 for myogenin and alpha-tubulin detection and 1:20 
000 for MyHC detection for 1 hour. HRP activity was visualized using Enhanced 
Chemiluminescence (ECL, BioRad, 170-5070) and GeneSys Image Acquisition software 
(Vacutec, South Africa). Densitometric analysis was carried out using the Versa Doc 
Imaging System and Quantity One 2.6 (Bio-Rad). 
 
2.2.8 Statistical Analysis  
 
The results from each experiment were expressed as a Mean ± SEM. The ANOVA statistical 
test was performed on all data followed by the Tukey’s pairwise post hoc test on all 
qualifying data sets. Samples were considered to be statistically significant if they produced 







2.3.1 C2C12 myoblast differentiation is regulated by HGF 
To determine the downstream effect of HGF on terminal myogenic differentiation, we first 
assessed C2C12 myotube fusion and sarcomeric myosin heavy chain (MyHC) expression at 
day 5 of differentiation.  
 
Myotube formation occurred in response to all doses of HGF with the highest levels of 
densely packed, aligned myotubes observed in response to 10 ng/ml HGF (Figure 2.1A). 
Fewer MyHC-expressing myotubes were observed in response to 2 ng/ml HGF, along with 
reduced alignment and reduced MyHC expression (Figure 2.1A). Under control conditions, 
the fusion index for C2C12 was 42% (Figure 2.1B), in line with independently published 
studies (Velica and Bunce, 2011). Treatment with 10 ng/ml HGF significantly (p<0.05) 
increased tube formation by 12%; in contrast 2 ng/ml HGF significantly reduced tube 
formation by 17% in response to 2 ng/ml HGF compared to the control (p<0.002) (Figure 
2.1B). These data was supported by a 30% increase in total MyHC expression in C2C12 
cells treated with 10 ng/ml HGF when compared to control (p<0.05; Figure 2.1C). 
Furthermore, a 20% reduction in MyHC production was observed when C2C12 cells were 




























2.3.2 HGF regulates c-Met receptor expression during myoblast differentiation 
In order to gain insight into the mechanism by which HGF may be mediating its effect on 
myogenesis, we analysed c-Met expression in differentiating C2C12 cells. 
 
A correlation between c-Met expression and HGF concentration was observed. In response 
to 2 ng/ml, c-Met expression was significantly suppressed by 30% at day 1 of differentiation 
(p<0.05; Figure 2.2A). In contrast, cells treated with 10 ng/ml HGF demonstrated a 20% 
increase in c-Met expression at day 1 (p<0.05; Figure 2.2A). The significant decrease in c-
Met expression in response to 2 ng/ml HGF was maintained through day 2 (p<0.005; Figure 
2.2B), whereas the increase in response to 10 ng/ml HGF is lost (p=0.484; Figure 2.2B). By 
day 5 of differentiation, c-Met receptor expression levels had equalised and there was no 
significant difference between control and HGF treated cells (Figure 2.2C). This data 
suggests that the observed dose dependent effect of HGF on myoblast differentiation may be 













































2.3.3 Inhibition of ERK, modulates the dose-dependent effect of HGF on C2C12 myoblast 
differentiation 
Intracellular pathways known to mediate HGF signalling include the MAPK’s as well as 
PI3K. In an effort to begin to clarify the intracellular mechanisms underlying the observed 
dose-dependent response of differentiating myoblasts to HGF, we utilised the PI3K inhibitor 
(LY294002), p38 inhibitor (SB205380), JNK inhibitor (SP600125) and ERK inhibitor 
(PD98059). 
 
LY294002, SB205380 and SP600125, but not PD98059, were observed to reduce C2C12 
differentiation in the presence or absence of HGF (Figure 2.3). Myosin heavy chain (MyHC) 
expression and the presence of fused myotubes were greatly reduced in cells treated with 
these inhibitors regardless of HGF exposure (Figure 2.3). Interestingly, PD98059 was 
observed to abrogate the negative effect of 2 ng/ml HGF on MyHC expression, suggesting 
that the ERK signaling pathway may be responsible, at least in part, for the inhibitory effect 


















































2.3.4 HGF regulates myoblast proliferation in a dose-dependent manner  
Next we tested whether the dose-dependent effect of HGF was restricted to differentiation, or 
whether HGF also played a key role within the myoblast proliferation cycle. Myoblasts were 
seeded at 100 000 cells per well and cultured in the presence or absence of 2 or 10 ng/ml 
HGF for 24 hours prior to cell counts. Compared with control, C2C12 myoblast numbers 
were significantly increased in response to 2 ng/ml HGF (p<0.05), but decreased following 
incubation with 10 ng/ml HGF (p<0.05) (Figure 2.4A). Cell counts revealed a significant 
21% increase, from 3.9x105 cells to 4.7x105 cells (Figure 2.4A; p<0.05) in response to 2 
ng/ml HGF compared to the untreated control. However, following incubation with 10 ng/ml 
HGF, a significant reduction in C2C12 myoblast numbers was observed (p<0.05) (Figure 
2.4A). Cell counts revealed a significant 40% decrease; from 3.9x105 cells to 2.4x105 cells 
(Figure 4A; p<0.05) in response to 10 ng/ml HGF. Interestingly, cells incubated in the 
presence of HGF (2 ng/ml) showed a small, but significant increase in C2C12 cell viability 
from 84% (control) to 89% (p<0.003; Figure 2.4B). HGF at 10 ng/ml did however not 
significantly affect cell viability when compared to control (84%) (Figure 2.4B). It is 
therefore possible that at least part of the ability of HGF to promote cell growth is due to a 
pro-survival rather than a pro-proliferative mechanism. Analysis of c-Met expression levels 
in proliferating C2C12 cells revealed a significant increase in cells treated with 10 ng/ml 
HGF, but not 2 ng/ml HGF (Figure 4C). This suggests that the anti-proliferative effect of 




































2.3.5 ERK and JNK mediate pro-proliferative effects of HGF 
To determine the role of MAPK and PI3K pathways in mediating the effect of HGF on 
proliferation, we next inhibited PI3K, ERK, p38 and JNK signaling pathways while 
incubating proliferating C2C12 cells with 0, 2 or 10 ng/ml HGF. PD98059 and SP600125 
(ERK and JNK inhibitors respectively) significantly reduced the pro-proliferative effect of 2 
ng/ml HGF (p<0.005) such that when treated with 2 ng/ml HGF and either PD98059 (12.5 
µM) or SP600125 (5 µM), the ability of HGF to significantly increase C2C12 cell numbers 
was abolished (Figure 2.5A and B). This suggests that the pro-proliferative effect of 2 ng/ml 
may be facilitated, at least in part, by the ERK and JNK pathways; however, these pathways 
seem to play little role in mediating the anti-proliferative effect of 10 ng/ml HGF in C2C12 
cells. Interestingly, inhibition of the JNK pathway also significantly (p<0.05) reduced cell 
viability in the presence of 2 ng/ml HGF (Figure 2.5D, p<0.05). Therefore, in addition to 
mediating myoblast proliferation, HGF may also act as a pro-survival factor via the JNK 





















































2.3.6 Inhibition of the PI3K and p38 pathways negates the effect of HGF on myoblast 
proliferation 
LY294002 and SB203580 (PI3K and p38 inhibitors respectively) were observed to 
neutralize both the pro- and anti- proliferative effects of HGF (Figure 2.6A and B). 
LY294002 (2.5 µM) and SB203580 (5 µM) significantly reduced the pro-proliferative effect 
of 2 ng/ml HGF (p<0.05) such that, when treated with 2 ng/ml HGF and either LY294002 or 
SB203580, the ability of HGF to significantly increase C2C12 cell numbers was abolished 
(Figure 2.6A and B). LY294002 (2.5 µM) and SB203580 (5 µM) also significantly decreased 
the anti-proliferative effect of 10 ng/ml HGF (Figure 2.6A and B). Under these conditions, 






















































Satellite cell activation, proliferation and subsequent skeletal myoblast differentiation are 
critical for successful myogenesis following muscle injury in adult mammals. In this regard, 
the relationship between growth factors and myogenesis has been extensively investigated in 
vitro using primary culture myoblasts and myogenic cell lines (Nadal-Ginard, 1978, Florini 
et al., 1996, Florini et al., 1991, Coolican et al., 1997, Linkhart et al., 1981, Zanou and 
Gailly, 2013, Jimenez-Amilburu et al., 2013). It is also well established that myogenesis in 
tissue culture is accompanied by an irreversible withdrawal from the cell cycle resulting in 
commitment of post-mitotic myoblasts to fusion and formation of multinucleated myotubes 
(Zammit et al., 2006a). The local concentration of growth factors supplied endogenously (by 
interacting cells) or exogenously (recombinant protein addition) is therefore critical for 
maintaining cells in a proliferative state or, alternatively, inducing differentiation (Florini et 
al., 1991). HGF, a key growth factor during myogenesis, has been shown to regulate satellite 
cell activation, proliferation and differentiation (Anastasi et al., 1997, Gal-Levi et al., 1998, 
Yamada et al., 2010). However, several discrepancies have arisen with regard to the effect of 
particular HGF doses on myogenesis (O'Blenes et al., 2010, Yamada et al., 2010, Anastasi et 
al., 1997, Gal-Levi et al., 1998, Bandow et al., 2004). This may be due to differences in the 
cell species used or in divergent extracellular environments, leading to changes in the type of 
intracellular signalling pathway activated. Furthermore, very few studies have investigated 
the expression of the c-Met receptor in response to HGF during myoblast proliferation and 
differentiation. In the present study we have investigated the effect of HGF on proliferation 
and differentiation in murine C2C12 myoblasts. Furthermore, we determined the expression 
of c-Met in response to HGF under these conditions and then attempted to understand the 
signaling mechanisms at play by selectively inhibiting specific signalling pathways 
downstream of c-Met. 
 
In response to HGF we observed a dose-dependent effect in mouse C2C12 skeletal 
myoblasts. In essence, the lower HGF concentration (2 ng/ml) significantly increased cell 
number (promoting a proliferative response) while decreasing myogenic commitment and 
subsequent differentiation and fusion. In contrast, a five-fold higher concentration of HGF 
(10 ng/ml) had the opposite effect, with a decrease in cell number and an increase MyHC 
expression, resulting in increased fusion. This is the first study to investigate the dose-
dependent effect of HGF on both proliferation and differentiation in mouse skeletal 
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myoblasts and demonstrates a complementary dose-dependent regulatory system coordinated 
by HGF.  
 
The premise that HGF plays a dual role in regulating myogenic proliferation and 
differentiation is not new. HGF has been well documented in activating quiescent satellite 
cells to proliferate and differentiate (Miller et al., 2000, Allen et al., 1995, Tatsumi et al., 
1998). In a study by Yamada et al. (2010), satellite cells were observed to respond to high 
concentrations of HGF (10-500 ng/ml) by increasing myostatin protein expression and 
secretion; this was accompanied by a decreased cell proliferation and MyoD expression in 
primary cultures suggesting a re-entry into a quiescent state. Yamada et al. (2010) 
hypothesize that this re-entry into quiescence could be via the observed increase in myostatin 
expression. This was proposed as neutralising antibodies (against myostatin) allowed cells to 
re-express MyoD and myogenin, even when incubated with higher concentrations of HGF 
(Yamada et al., 2010). In response to lower HGF concentration (2.5 ng/ml), BrdU 
incorporation was observed to increase, suggesting elevated proliferation; interestingly 
myogenin mRNA expression levels were reduced in response to both 2.5 ng/ml and 500 
ng/ml HGF compared with control, suggesting decreased induction of differentiation. In our 
present study, we demonstrate a decrease in myoblast cell number in response to 10 ng/ml 
HGF and a decrease in Myosin Heavy Chain expression in response to 2 ng/ml HGF; this is 
consistent with the observations of Yamada et al. (2010). However, in addition, 10 ng/ml 
HGF was observed to increase terminal differentiation as seen by the increased Myosin 
Heavy Chain expression (day 5). This has not previously been demonstrated.  Gal-Levi et al. 
(1998) observed a decrease in MyHC expression levels with increasing HGF concentrations 
in chicken satellite cells and a myogenic C2 cell line. This is not in agreement with our 
current study, however expression was determined over a 2 day period with HGF 
concentrations of 20 and 50 ng/ml, exceeding our highest HGF dose. It can therefore be 
hypothesized, that a temporal increase in extracellular concentrations of HGF (as would be 
experienced post-injury) is key in the modulation of satellite cell activation and subsequent 
differentiation. Together, these results suggest an intriguing dose-dependent regulatory effect 
of HGF on the balance between quiescence and activation as well as proliferation and 
differentiation. 
 
HGF binds to the c-Met receptor, a membrane-bound, disulfide-linked heterodimer with an 
intracellular tyrosine kinase domain, found on both quiescent and activated satellite cells 
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(Giordano et al., 1989, Cornelison and Wold, 1997). Results by Leshem et al. (2002) have 
shown that coupling of c-Met with Grb2 is required for inhibition of muscle differentiation 
mediated by HGF. This inhibition occurred only when Phosphatidylinositol 3-Kinase (PI3K) 
signalling downstream of c-Met was low, suggesting that increased coupling of PI3K to c-
Met would lead to an up-regulation of muscle regulatory factors, such as MyoD, thereby 
promoting cell differentiation (Leshem et al., 2002, Maina et al., 2001). This supports our 
observed increase in c-Met expression levels at the onset of myogenic commitment (day 1) 
in response to 10 ng/ml HGF. Our findings suggest that subsequent dose-dependent 
regulation of differentiation by HGF is possibly correlated with total c-Met receptor level 
expression with an observed significant drop in c-Met receptor levels in samples incubated 
with 2 ng/ml HGF at day 1 and day 2. Although HGF is the dominant binding factor to c-
Met, there are a multitude of signalling adaptors (Grb2, Gab) and cell surface co-receptors, 
such as CD44, ICAM-1 and several integrin’s, which mediate biological responses unique to 
c-Met (Organ and Tsao, 2011). Studies in epithelial and cancer cells have shown that in this 
way, despite constant c-Met expression levels, HGF can elicit differential effects via 
downstream signalling mediators (Organ et al., 2011, Hammond et al., 2010).  
 
Potential downstream pathways that have been suggested to mediate the dose-dependent 
effect of HGF on myogenesis include PI3K, p38, JNK and ERK (Halevy and Cantley, 2004). 
Furthermore, PI3K activity is required for HGF-induced MAPK activation, adding an 
additional layer of complexity (Halevy and Cantley, 2004). We attempted to glean a better 
understanding of the mechanisms involved in the dose-dependent effect of HGF on C2C12 
proliferation and differentiation by utilizing specific inhibitors against some of the above-
mentioned pathways.  
 
We showed that the addition of LY294002 decreased C2C12 myoblast fusion, irrespective of 
HGF dose. Our findings were supported by Jiang et al (1999) and Sumitani et al (2002) who 
reported LY294002, and resulting inhibition of Akt, interfered with myotube formation and 
the expression of muscle-specific proteins such as MyoD and MyHC (Jiang et al., 1999, Li et 
al., 2000, Sumitani et al., 2002). Furthermore, we showed that addition of 2.5 µM LY294002 
to proliferating C2C12 cells treated with either 2 ng/ml HGF and 10 ng/ml HGF abrogated 
the effect of this growth factor on cell number. This result was expected in part due to the 
known involvement of the PI3K/AKT pathway in myoblast proliferation, survival and 
regulation of apoptosis (Mandl et al., 2007).  
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We observed that the addition of PD98059 reduced the negative effect of 2ng/ml HGF, on 
differentiation, confirming that the ERK signaling pathway may mediate, at least in part, the 
inhibitory effect of HGF on myogenesis (Yang et al., 2006). Our study also showed that 
PD98059 modulated the pro-proliferative effect of 2 ng/ml HGF on C2C12 myoblasts. IGF-1 
has been observed to activate the ERK pathway and lead to increased proliferation of mouse 
primary culture myoblasts (Madhala-Levy et al., 2012). This, together with our results 
strongly suggests that the pro-proliferative effect of 2 ng/ml HGF is regulated, at least in part, 
by the ERK pathway. It has also been demonstrated that PI3K activity is required for HGF-
induced MAPK activation; this adds an additional layer of complexity and may explain why 
LY294002 is able to affect both pro- and anti-proliferative pathways in myoblasts (Halevy 
and Cantley, 2004). 
 
Li et al (2000) had also previously shown that p38 inhibition prevents myogenic 
differentiation (Li et al., 2000). Similarly, our results showed that SB205380 reduced 
myotube formation further supporting the notion that p38 is vital for effective C2C12 
differentiation. However, as with LY294002, the inhibition was independent of HGF. In our 
proliferation studies, SB203580 was able to negate both the positive and negative effects of 
HGF on cell numbers. In support of our findings, Jones et al (2005) found that p38 is vital to 
the activation of primary culture satellite cells and their subsequent proliferation. Inhibition 
of p38 with SB203580 drove MM14 cells towards a quiescent-like state where they exit the 
cell cycle, but fail to differentiate (Jones et al., 2005). These results underscore the 
importance of keeping in mind that changes in cell number are determined by numerous 
contributing factors, not proliferation alone. 
 
We showed that inhibition of JNK with SP600125 abolished the pro-proliferative effect of 2 
ng/ml HGF and prevented C2C12 fusion, regardless of HGF treatment. Interestingly, cell 
viability was reduced when JNK was inhibited with SP600125, further supporting JNKs’ 
well-documented role in cell survival. These results suggest that not only does the inhibition 
of JNK mediate HGF-induced proliferation, but also that this effect is compounded by a 






Figure 2.7: Schematic representation of our findings. A) 2 ng/ml HGF promotes proliferation in C2C12 
myoblasts through the PI3K, JNK, ERK and p38 pathways. We have shown that inhibition of these pathways 
reverses the pro-proliferative effect of 2 ng/ml HGF on C2C12 cells. B) 10 ng/ml HGF inhibits proliferation in 
C2C12 myoblasts through the PI3K and p38 pathways. We have shown that inhibition of these pathways 
reverses the anti-proliferative effect of 10 ng/ml HGF on C2C12 cells.  C) 2 ng/ml HGF inhibits fusion in 
C2C12 myoblasts. D) 10 ng/ml HGF promotes fusion in C2C12 myoblasts. 
 
In conclusion, our findings support a role for HGF in regulating both myoblast cell number 
and terminal differentiation in a dose-dependent manner (Figure 2.7). However, we further 
suggest that not only does HGF regulate these processes, but that proliferation and 
differentiation in C2C12 mouse myoblasts can be either promoted or inhibited in response to 
changing exogenous HGF concentrations. Changes in c-Met receptor expression were noted 
in response to HGF and the dose-dependent effects of the growth factor on proliferation and 
differentiation could be correlated to expression levels of this receptor. Furthermore, our 
results suggest that P13K and p38 mediate the anti-proliferative effect of the higher dose 
HGF, whereas the ERK signalling pathway is, at least in part, responsible for the negative 








It is becoming increasingly apparent that the extracellular matrix (ECM) of skeletal 
muscle, in addition to providing structural support, provides regulatory cues to the 
resident satellite cell population and thereby modulates activation and subsequent 
myogenesis. Satellite cells reside between the basal lamina and sarcolemma where they 
interact with matrix factors of their niche. Collagen IV and laminin, the major 
components of the basal lamina, bind to and interact with satellite cells via integrin’s 
and other cell surface proteins. Of particular interest to us is CD9, a tetraspanin 
transmembrane protein expressed on myoblasts and known to interact with collagen IV. 
In the current study we first analyzed the effect of Matrigel (an exogenous mixture of 
factors that simulates the basal lamina ECM), as well as its two main constituents, 
laminin and collagen IV, on fusion. We then analyzed the role of key myogenic 
transcription factors as well CD9 in an effort to understand the mechanism underlying 
the effects observed. Matrigel and collagen IV (the second largest constituent of 
Matrigel), but not laminin, significantly increased terminal fusion of C2C12 myoblasts. 
Collagen IV was observed to significantly increase percentage MyoD+ cells without 
affecting Pax7+ cell numbers. Furthermore collagen IV stimulated an increase in CD9 
expression on differentiating cells such that cells cultured on collagen IV required 
higher levels of neutralizing anti-CD9 monoclonal antibodies to reduce fusion. These 
results identify the interaction of collagen IV with CD9 as a critical mediator of skeletal 
muscle myogenesis.  
 
Includes data from: 
Walker NL and Niesler CU. Collagen IV promotes myoblast fusion in a CD9-dependent 
manner [Contributed all data and analysis of figures in the paper]. Submitted, Matrix 






Satellite cells reside in quiescence in their niche between the basal lamina and the 
sarcolemma of a muscle fiber (Mauro, 1961). The extracellular matrix of the satellite cell 
niche is known to regulate stem cell self-renewal and differentiation in vivo, however, the 
mechanism by which it does so is unclear (Dellatore et al., 2008). The importance of the 
niche ECM in stem cell behavior is outlined by the fact that disruption of its components 
results in defective regeneration in the majority of stem cell types in the body (Jones and 
Wagers, 2008). In addition to providing structural support to the niche, the ECM plays a vital 
role in mediating the availability of growth factors, thereby regulating stem cell quiescence 
and activation (Thomas et al., 2015). The complexity of the in vivo niche makes it difficult to 
fully understand the roles of individual components, therefore individual ECM factor and 
simple combination studies are required. In this study we examine the role of collagen IV, 
the major collagen component of the basal lamina, on myoblast behavior. 
 
Collagen IV is essential for basement membrane stability and serves as the main scaffold 
material of the niche ECM (Poschl et al., 2004). Through molecular interactions with 
integrins, collagen IV is able to influence cell fate in developing and adult tissues 
(Khoshnoodi et al., 2008). Embryoid body formation is the principle step in the 
differentiation of embryonic stem cells and it has been shown that collagen IV (10 µg/ml) 
supports this formation (Taru Sharma et al., 2012). Schenke-Layland et al (2007) 
demonstrated that collagen IV was able to direct early embryonic stem cell differentiation 
towards smooth muscle lineages in both mouse and human embryonic stem cells (Schenke-
Layland et al., 2007). With regard to skeletal muscle, collagen IV is found exclusively in the 
basement membrane (Foidart et al., 1981). Recent studies have shown that collagen IV is 
able to increase migration and viability in insulin like growth factor I (IGF-1) gene 
engineered C2C12 cells (Ito et al., 2015). Collagen IV also significantly increased fusion and 
the number of myotubes displaying striations in samples stimulated to express IGF-1, as well 
as increasing the displacement of electrical pulse stimulated myotubes (Ito et al., 2015). This 
suggests that collagen IV can enhance the contractile ability of myoblasts in vitro. 
 
Laminins are a group of basal lamina proteins and are composed of a heavy α-chain and two 
light chains, β and γ. Laminin-211 (merosin) is the subtype found around the sarcolemma of 
muscle fibers and is known to bind to collagen IV in the basal lamina (Grounds et al., 2005). 
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Laminin-211 deficiency is well documented in congenital muscle dystrophies (Guo et al., 
2003). Laminin-111, which differs from laminin-211 only in its alpha domain, has been 
shown to promote the migration of C2C12 cells in vitro (Yao et al., 1996). However the 
effect of laminin-111 on the differentiation of C2C12 cells remains a topic of debate. Grossi 
et al (2007) utilized a magnetic bead stimulation model whereby beads were coated with 10 
µg/ml laminin-111 and allowed to interact with differentiating C2C12 cells in a magnetic 
field. This method supplied both chemical stimulation via laminin interactions and 
mechanical stimulation via magnetic bead contact. They observed a 1.5 fold increase in 
MyoD and myogenin expression when compared to mechanical stimulation with uncoated 
beads. However, this study revealed that incubation of C2C12 cells on plates coated with 10 
µg/ml laminin-111 without mechanical stimulation did not result in increased myotube 
formation (Grossi et al., 2007). This suggests that, in a 2D environment, signaling through 
the laminin receptor alone is not enough to increase C2C12 differentiation. This is in contrast 
to Foster et al (1987) who showed that laminin-111 enhances skeletal myogenesis when rat 
hindlimb tissue was cultured on plates coated with 10 µg/ml laminin-111. Here, whole 
muscle fibers were isolated and injured, and improved wound healing was observed in vitro. 
It was however concluded that this effect was due to the selective promotion of myoblast 
proliferation by laminin rather than increased myogenic potential of the myoblast population 
(Foster et al., 1987).  
 
Matrigel, an exogenous mixture of proteins secreted by Engelbreth-Holm-Swarm (EHS) 
mouse sarcoma cells, closely mimics the components of the basal lamina. Matrigel is 
commonly utilized to improve the proliferative and myogenic potential of isolated primary 
culture myoblasts. Langen et al (2003) demonstrated that by merely reducing the media 
serum component and culturing C2C12 cells on Matrigel, significantly reduced C2C12 
proliferation and improved myogenesis can be achieved when compared to protocols 
involving the use of horse serum on uncoated plates (Langen et al., 2003). Furthermore, it 
has been shown to improve the fusion of C2C12 myoblasts into myotubes in vitro (Grefte et 
al., 2012). Grefte et al (2012) differentiated primary culture myoblasts isolated from 
Sprague-Dawley rats on 1 mg/ml Matrigel and observed 35% increase in fusion when 
compared to non-treated controls after just three days. Fusion reached 50% by day 5 cultured 
on Matrigel (Grefte et al., 2012).  
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CD9 is a member of the tetraspanin family of transmembrane proteins and is known to bind 
to collagen IV (Tachibana and Hemler, 1999). Tetraspanins, also known as the 
transmembrane 4 superfamily, are believed to act as a molecular scafford with a role in 
binding specific proteins to one another on the cell surface (Hemler, 2005). Blocking of CD9 
using neutralizing monoclonal antibodies has been shown to delay the fusion of C2C12 cells 
into myotubes (Tachibana and Hemler, 1999). Furthermore, Charrin et al (2013) have shown 
that disruption of CD9 expression in knockout mice results in disorganized and abnormal 
muscle regeneration characterized by the formation of large dystrophic muscle fibers 
(Charrin et al., 2013). This suggests that CD9 is vital for the efficient progress of myogenesis. 
 
In the current study we determined whether the pro-myogenic effects of Matrigel can be 
ascribed to either one of its major components, collagen IV or laminin-111. We then 
examined potential mechanisms for the effects observed, notably by analyzing myogenic 
transcription factor and CD9 expression. Our findings suggest a novel role for CD9 in 





















3.2 Materials and methods: 
 
All reagents were of an analytical grade and obtained from Sigma-Aldrich (USA), unless 
stated otherwise. All cell culture was performed under sterile conditions in a level II 
biological safety cabinet (ESCO Class II BSC). 
 
3.2.1 Cell Culture 
 
The C2C12 murine cell line was purchased from the American Type Culture Collection 
(ATTC, CRL-1772). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (Highveld 
Biological, CN3193-9) supplemented with 10% (v/v) Fetal Bovine Serum (Biowest, S181H-
500), 2% (v/v) L-glutamine (Lonza, BE17-605E) and 2% (v/v) Penicillin-Streptomycin 
(Lonza, DE17-602E). For differentiation studies, cells were cultured to a confluence of 70% 
after which media was changed to differentiation media (DMEM supplemented with 2% 




Differentiation media consists of 485 ml DMEM, 10 ml PenStrep (2% v/v) and 5 ml horse 
serum (16050-130; Invitrogen; USA) filter sterilized prior to storage in 50 ml falcon tubes at 
4°C. When cells reached approximately 70% confluence, the media was changed to 
differentiation media. Cells were maintained at 37 °C, 5% CO2 in a humidified incubator.  
 
3.2.3 ECM Coating 
 
T25 culture flasks and 24 well plates containing glass coverslips were coated with 3 ml and 
500 µl respectively with the solutions described below. All plates were incubated at 37 °C 
for 4 hours, before the protein solutions were removed and the plates allowed to air dry 
under U.V. light overnight. Plates and wells are washed with sterile PBS before use and 
stored at 4 °C for no longer than a month.  
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  3.2.3.1 Collagen IV Coating 
Collagen IV solution (Human; 0.3 mg; C6745; Sigma-Aldrich; USA) was diluted to a stock 
solution of 0.1 mg/ml with sterile PBS at 4 °C. This stock was then diluted further to the 
desired concentration range (12.5, 25 and 50 µg/ml) with sterile PBS.  
 
  3.2.3.2 Laminin-111 Coating 
Laminin solution (Mouse; 1 mg; L2020; Sigma-Aldrich; USA) was diluted to a stock 
solution of 0.1 mg/ml with sterile PBS at 4 °C. This stock was then diluted further to the 
desired concentration range (6.25, 12.5 and 25 µg/ml) with sterile PBS.  
 
  3.2.3.3 Matrigel Coating 
A cold 10.1 mg/ml Matrigel solution (CN-354230; BD Biosciences; USA) was diluted to a 
stock concentration of 0.6 mg/ml in double distilled water. This stock was then diluted 
further to the desired concentration range (30, 60 and 120 µg/ml) with sterile PBS. All 
dilutions and coating procedures were done on ice. 
   
A Clustal W alignment was conducted to compare the amino acid sequences of human 
collagen IV used in this study and collagen IV found in mice (Mus Musculus) (Appendix III). 
A score of 79.2899 showed that the amino acid sequence of human collagen IV is highly 
similar to mouse collagen IV. 
 
3.2.4 Immunocytochemistry and Confocal Microscopy 
 
C2C12 cells were plated onto coverslips in a 24 well plate and allowed to reach 70% 
confluence in 500 µl growth media. Wells had previously been coated with the ECM factors 
as described earlier. HGF addition took place with initial plating out and at all media changes 
(day -1, 0 and 3). Differentiating (day 1, day 2 and day 5) cell samples were cultured in 
differentiating media for 24, 48 and 120 hours respectively. Coverslips were subsequently 
washed with PBS and fixed with 4% paraformaldehyde for 15 minutes. They were then 
washed with PBS and blocked using 5% donkey serum. Coverslips were then incubated with 
primary antibodies for 4 hours at room temperature: day 0/1: mouse monoclonal anti-Pax7, 
mouse monoclonal anti-CD9; day 2: rabbit polyclonal anti-MyoD; day 5: mouse monoclonal 
anti-MyHC, mouse monoclonal anti-CD9 (see table 3.1 for optimized dilutions). Coverslips 
 54 
were then washed 4 x 8 minutes with PBS before being incubated with appropriate 
secondary antibody for 40 minutes (Table 3.1). These were washed 3 x 8 minutes with PBS 
before being treated with Hoechst 33342 nuclear stain (Stock: 10 mg/ml; 1/4000; Sigma-
Aldrich; USA). Coverslips were then washed for a further 4 x 8 minutes with PBS before 
being mounted with Moviol and finally visualized using the Zeiss LSM 710 confocal 
microscope. 
Table 3.1: Antibody concentrations (optimized) used in Confocal microscopy 





Mouse monoclonal anti-Pax7 
(ab55494; Abcam; UK)  
1/500 Donkey anti-mouse Dylight 488 
 (715-485-151, Jackson ImmunoResearch) 
1/1000 
Rabbit polyclonal anti-MyoD (sc-760, 
Santa Cruz; USA) 
1/100 Donkey anti-rabbit Dylight 488 
  (711-455-152, Jackson ImmunoResearch) 
1/1000 
Mouse monoclonal anti-MyHC (MF-
20; DSHB; USA) 





Donkey anti-mouse Dylight 494 
 (715-515-151, Jackson ImmunoResearch) 
Donkey anti-mouse Dylight 488 





3.2.4.1 Assessment of percentage Pax7+ and MyoD+ cells  
 
Cells shown to be expressing nuclear Pax7 or MyoD were counted and determined as a percent 
of total nuclei on proliferating (percentage Pax7+), day 1 (percentage Pax7+) and day 2 
(percentage MyoD+) differentiating cultures. Due to the fact that Pax7 is expressed in 
proliferating myoblasts and down-regulated following induction to differentiate, Pax7 
assessment was not conducted beyond day 1 of differentiation (Zammit et al., 2006b). 
Additionally, MyoD expression was examined at day 2 of differentiation as MyoD expression 
has previously been shown to peak at day 2 of differentiation in C2C12 myoblasts (Panda et al., 
2014). Images were examined using Zen software (Zeiss) allowing visualization of a single 
plane (either Pax7 or nuclear staining) and accurate quantification. Approximately 20 cells per 
image were analysed and a minimum of 5 fields of view (i.e. 100 cells/n), randomly selected, 
were used for n=1. Experiments were repeated n = 6-8 times. 
 
3.2.4.2 Assessment of terminal differentiation via a fusion index  
 
The fusion index was determined via quantitative analysis of confocal images of differentiated 
myotubes (day 5). Images were exported using Zen software (Zeiss) as a single plane with both 
the red channel (MyHC) and the blue channel (Hoechst). This allowed us to count the number 
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of nuclei in fused myotubes (containing 2 or more nuclei). This number was divided by the 
total number of nuclei in the field of view and multiplied by 100. A minimum of 4 fields of 
view, randomly selected, were used for n=1. Experiments were repeated n = 6-8 times. 
 
3.2.5 Protein separation by SDS-PAGE 
 
Lysate sample preparation is outlined in Appendix IV. The Laemmli protocol was used for 
SDS-PAGE (Laemmli, 1970) with several modifications outlined in Appendix IV. The 
BioRad electrophoresis unit (BioRad; Mini-PROTEIN 3 Cell; USA) was utilized for the 
running of all polyacrylamide gels. 10% or 12.5% gels were cast between two glass plates, as 
described in the Appendix IV, and allowed to solidify (~1 hour) before the stacking gel was 
added with a 10 fingered comb to create the lanes for sample loading. Once the stacking gel 
had set (~30 minutes) the comb was gently removed and lanes washed with distilled water. 
Electrode (tank) buffer was poured into the inner and outer electrode compartments before 
the prepared samples were loaded. The samples were prepared by adding an equal volume of 
reducing sample treatment buffer to the sample and boiling the solution for 2 minutes. 
Samples were then stored on ice until loaded. 1 µl bromophenol blue (1437500CB; 
Saarchem; RSA) was added to each sample so that the buffer front could be clearly discerned. 
25 µg of protein per lane was added to the gel as determined by the Bradford Assay 
(Appendix IV). 3 µl of the PeqGold protein marker V (27-2210; Peqlab; Germany) was run 
in at least one lane of each gel for later determination of protein molecular weights. Gels 
were run at 4 °C with 18 mA per gel until the buffer front reached the bottom of the running 
gel. The gel was removed from between the glass plates and either stained with the 
Coomassie G-250 stain or processed for western blot analysis.  
 
3.2.6 Western Blot analysis of CD9 
 
Cells were differentiated on collagen IV coated and non-coated T25 culture flasks for up to 5 
days. Proteins were separated in a 12% SDS-PAGE gel and transferred to nitrocellulose. The 
nitrocellulose was then blocked in 5% (m/v) low fat milk powder (made up in TBST) for 1 
hour. Primary antibody (Mouse monoclonal anti-CD9, BD 551808, USA) was made up in 
TBST was then added to the nitrocellulose for 2 hours. GAPDH (Cell signalling, 2118) was 
used as a loading control. This was followed by wash steps with TBST (4 x 8 minutes). All 
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wash steps were performed with vigorous agitation. HRPO-linked secondary antibody (Rabbit 
anti-mouse IgG, Dako, P016102, USA) made up in TBST was then added for 1 hour. This was 
followed by washing with TBST (6 x 8 minutes).  
 
Enhanced Chemiluminescence (ECL) technique was used for the development of the bands. 
Light film (Kodak BioMax light film; Z370398; Sigma-Aldrich; USA) was utilized. The 
substrate was made by adding peroxide and enhancer solutions in a 1:1 ratio (Immun-Star 
WesternC; 70-5070; Bio-Rad, USA). The substrate (1 ml) was added to the nitrocellulose for 
2 minutes. Prior to development, the developer (Structurix G128; Agfa; 5TBN; Belgium) and 
the fixative (G333c Rapid Fixer; Agfa; EGCQT; Belgium) solutions were made up with 




The bands that developed on the film were analyzed by use of computer software (Image J, 
http://imagej.nih.gov/ij/). Densitometric analysis was selected and the background was 
adjusted so that only the bands were visible for all experiments.  
 
3.2.7 Monoclonal antibody blocking 
 
C2C12 myoblasts (15 000 cells/well) were plated in collagen IV-coated and non-coated 
wells of a flat-bottom 96 well culture plate (Corning, CR/3596) and allowed to reach 70% 
confluence. Media was then replaced with diffferentiation media containing mouse 
monoclonal anti-CD9 (BD 551808, USA; 0, 1/1600, 1/800, 1/1600 dilution) and allowed to 
differentiate for 7 days. Media (containing various dilutions of mAbs) was replaced every 2 
days.  
 
3.2.8 Statistical analysis 
 
The results from each experiment were expressed as a Mean ± SEM. The student’s t-test was 
performed on all data. Samples were considered to be statistically significant if they 




3.3.1 Matrigel increases terminal fusion of C2C12 myoblasts 
Matrigel is a commercially available protein mixture that closely mimics the basal lamina. It 
is composed mainly of laminin-111 and collagen IV that together make up 90% of its total 
mass (Yu and Machesky, 2012). To determine the effects of Matrigel on C2C12 cell terminal 
differentiation, cells were cultured on Matrigel (0, 30, 60 and 120 µg/ml) and the effects on 
fusion determined by confocal microscopy. Matrigel (30 and 60 µg/ml) visibly increased 
differentiation (Figure 3.1A); calculation of percentage fusion at day 5 revealed a significant 
increase from 42 ± 3% (control) to 65 ± 3% (30 µg/ml, p < 0.005) and 66 ± 2% (60 µg/ml, p 
< 0.005) (Figure 3.1B). This confirms the ability of Matrigel to positively modulate terminal 
differentiation. 
 
Figure 3.1: C2C12 myoblast differentiation in response to Matrigel. C2C12 myoblasts were incubated in 
growth media on Matrigel-coated glass coverslips (0, 30, 60 and 120 µg/ml) and allowed to reach 70% 
confluence. Cells were then induced to differentiate for 5 days prior to fixation. A) Representative images of 
differentiated C2C12 cells showing MyHC (red) and nuclei (blue). B) Fusion index calculated as percent 
C2C12 myotube formation at day 5 of differentiation.  Scale bar represents 50 µm. N = 6, all figures represent 
mean ± SEM, * = p < 0.05. 
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3.3.2 C2C12 cells down-regulate Pax7 expression in response to differentiation cues 
Activated, proliferating myoblasts express the paired-box transcription factors Pax7 and 
Pax3, as well as MyoD and myogenin (Le Grand and Rudnicki, 2007). Pax7 is known to 
play a role in the self-renewal pathway, which is responsible for ensuring a constant 
population of satellite cells in the tissue. It is expressed in both quiescent and activated 
satellite cells, but is down-regulated upon differentiation (Relaix et al., 2006). Down-
regulation of Pax7 results in a up-regulation in MyoD as cells begin to align for 
differentiation (Olguin et al., 2007). A subsequent down-regulation of MyoD and up-
regulation of myogenin and MyHC are the final molecular steps in differentiation of satellite 
cells into myotubes (Olguin et al., 2007). By examining the expression of these proteins in a 
population of cells, deductions regarding their progression of differentiation can be made. 
Maintained Pax7 expression has been shown to inhibit differentiation by interfering with the 
expression of critical myogenic transcription factors such as MyoD and myogenin (Olguin et 
al., 2007, Zammit et al., 2006b). In our study, differentiation cues visibly reduced the 
number of Pax7+ cells when compared to proliferating cells (Figure 3.2A). When quantified, 
under proliferative conditions 26 ± 5% of C2C12 myoblasts express nuclear Pax7 (Figure 
3.2B). In response to differentiation media (24h) there was a significant decrease in the 
percentage Pax7+ cells to 12 ± 4% (p < 0.035) (Figure 3.2B). 
 
Figure 3.2: Percentage Pax7+ cells in proliferating versus differentiating C2C12 cells. C2C12 myoblasts were 
plated onto glass coverslips in growth medium and allowed to reach 70% confluence. Cells were then either fixed 
for confocal microscopy or induced to differentiate for 1 day prior to fixation. Nuclear Pax7 expression was 
observed and expressed as a percentage of total cells. A) Representative images of C2C12 cells stained with anti-
Pax7 antibodies under proliferative conditions and after day 1 of differentiation. B) Graph showing percentage 
Pax7+ myoblasts under proliferative conditions and at day 1 of differentiation. Green arrows show Pax7+ cells. 
Red outlined circles represent nuclei. Scale bar represents 20 µm. N = 24, all figures represent Mean ± SEM, * = p 
< 0.05. 
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3.3.3 Matrigel does not affect Pax7 expression in differentiating C2C12 myoblasts 
To determine the effects of Matrigel on differentiating C2C12 Pax7 expression, C2C12 cells 
were cultured on Matrigel (0, 30, 60 and 120 µg/ml) and the effects on Pax7 expression 
determined by confocal microscopy. Pax7 expression appeared similar when Matrigel treated 
samples were compared to untreated controls (Figure 3.3A) and quantification revealed no 
significant changes in percentage Pax7+ cells (Figure 3.3B). Percentage Pax7 levels 
remained between 13 and 18% ± 4% for all treatments. 
 
Figure 3.3: Effect of Matrigel on Pax7 expression of C2C12 myoblasts. C2C12 myoblasts were plated in 
growth media on Matrigel-coated glass coverslips (0, 30, 60 and 120 µg/ml) and allowed to reach 70% confluence. 
Cells were then induced to differentiate for 1 day prior to fixation. A) Representative images of C2C12 cells 
stained with anti-Pax7 antibodies. B) Graph showing percentage Pax7+ myoblasts at day 1 of differentiation. Red 
outlined circles represent nuclei. Green arrow shows Pax7+ cells.  Scale bar represents 20 µm. N = 6, all figures 










3.3.4 Matrigel does not affect MyoD expression in differentiating C2C12 myoblasts 
To determine the effects of Matrigel on C2C12 commitment to differentiation, C2C12 cells 
were cultured on Matrigel (0, 30, 60 and 120 µg/ml) and the effects on MyoD expression 
determined by confocal microscopy. MyoD expression appeared visibly similar when 
Matrigel treated samples were compared to untreated controls (Figure 3.4A) and 
quantification revealed no significant changes in percentage MyoD + cells (Figure 3.4B). 
MyoD+ cell numbers remained between 45 and 51% ± 16% for all treatments. 
 
Figure 3.4: Effect of Matrigel on myogenic commitment of C2C12 myoblasts.  C2C12 myoblasts were plated 
in growth media on Matrigel-coated glass coverslips (0, 30, 60 and 120 µg/ml) and allowed to reach 70% 
confluence. Cells were then induced to differentiate for 2 days prior to fixation. A) Representative images of 
C2C12 cells stained with anti-MyoD antibodies. B) Graph showing percentage MyoD+ myoblasts at day 2 of 
differentiation. Red outlined circles represent nuclei. Green arrow shows MyoD+ cells.  Scale bar 50 µm. N = 6, 










3.3.5 Laminin does not affect fusion in differentiating C2C12 myoblasts 
Matrigel’s largest constituent, providing over 60% of its mass, is laminin (Haber et al., 1988). 
To determine whether the effect of Matrigel on terminal differentiation was due to its high 
laminin content, we examined the effects of varying concentrations of laminin-111 (0, 6.25, 
12.5 and 25 µg/ml) on C2C12 myoblasts. Laminin-111 did not visibly increase fusion levels 
(Figure 3.5A). Following quantification, no significant changes were observed in percentage 
fusion when C2C12 cells were cultured on laminin-111 (Figure 3.5B) when compared to 
control. Percentage fusion remained between 40 and 45% ± 10% for all treatments. This 
suggests that the effects observed in response to Matrigel (section 3.3.1) are not attributed to 
laminin-111. 
 
Figure 3.5: The effect of laminin-111 on the differentiation of C2C12 myoblasts. C2C12 myoblasts were 
plated in growth media on laminin-coated glass coverslips (0, 6.25, 12.5 and 25 µg/ml) and allowed to reach 
70% confluence. Cells were then induced to differentiate for 5 days prior to fixation. A) Representative images 
of differentiated C2C12 cells showing MyHC (red) and nuclei (blue). B) Fusion index calculated as percentage 
C2C12 myotube formation at day 5 of differentiation. Scale bar represents 50 µm. N = 6, all figures represent 






3.3.6 Collagen IV increases fusion of C2C12 myoblasts 
Matrigel’s second largest constituent, providing approximately 30% of its mass, is collagen IV 
(Haber et al., 1988). To determine the effects of collagen IV, Matrigel’s second largest 
constituent, on fusion, C2C12 cells were differentiated on varying concentrations of collagen 
IV (0, 12.5, 25 and 50 µg/ml) and fusion analysed by confocal microscopy. Collagen IV (25 
µg/ml) visibly increased terminal differentiation at day 5 (Figure 3.6A) which translated to a 
significant increase in fusion from 42% ± 3% to 59 ± 6% (p < 0.05, Figure 3.6B). This 
suggests that the effect of Matrigel on myoblast fusion may be mediated, at least in part, by 
collagen IV. 
 
Figure 3.6: The effect of collagen IV on the differentiation of C2C12 myoblasts. C2C12 myoblasts were 
plated in growth media on collagen IV-coated glass coverslips (0, 12.5, 25 and 50 µg/ml)  and allowed to reach 
70% confluence. Cells were then induced to differentiate for 5 days prior to fixation. A) Representative images 
of differentiated C2C12 cells showing MyHC (red) and nuclei (blue). B) Fusion index calculated as percentage 
C2C12 myotube formation at day 5 of differentiation. Scale bar represents 50 µm. N = 6, all figures represent 






3.3.7 Collagen IV does not affect Pax7 expression in differentiating C2C12 myoblasts 
To determine whether the effects of collagen IV on fusion (section 3.3.5) are mediated by 
changes in percentage Pax7+ cells, C2C12 cells were differentiated on varying 
concentrations of collagen IV (0, 12.5, 25 and 50 µg/ml) and analysed by confocal 
microscopy. Pax7 expression appeared similar when collagen IV treated samples were 
compared to uncoated controls (Figure 3.7A) and quantification revealed no significant 
changes in percentage Pax7+ cells (Figure 3.7B). Percentage Pax7 levels remained between 
14 and 17% ± 3% for all treatments observed. 
 
Figure 3.7: Effect of collagen IV on Pax7 expression of C2C12 myoblasts.  C2C12 myoblasts were plated in 
growth media on collagen IV-coated glass coverslips (0, 12.5, 25 and 50 µg/ml) and allowed to reach 70% 
confluence. Cells were then induced to differentiate for 1 day prior to fixation. A) Representative images of 
C2C12 cells stained with anti-Pax7 antibodies. B) Graph showing percentage Pax7+ myoblasts at day 1 of 
differentiation. Red outlined circles represent nuclei. Green arrow shows Pax7+ cells.  Scale bar represents 20 µm. 









3.3.8 Collagen IV increases MyoD expression in differentiating C2C12 myoblasts 
To determine whether the effects of collagen IV on fusion (section 3.3.5 are mediated by 
changes in percentage MyoD+ cells, C2C12 cells were differentiated on collagen IV (0, 12.5, 
25 and 50 µg/ml) and analysed by confocal microscopy. Collagen IV (25 µg/ml) was 
observed to visibly increase the %MyoD+ cells (Figure 3.8A). Quantitative analysis revealed 
that collagen IV (25 µg/ml) significantly increased %MyoD+ cells from 48% ± 7% to 67% ± 
4% MyoD+ cells at day 2 (p < 0.05, Figure 3.8B).  
 
Figure 3.8: Effect of collagen IV on myogenic commitment of C2C12 myoblasts.  C2C12 myoblasts were 
plated in growth media on collagen IV-coated glass coverslips (0, 12.5, 25 and 50 µg/ml) and allowed to reach 
70% confluence. Cells were then induced to differentiate for 2 days prior to fixation. A) Representative images of 
C2C12 cells stained with anti-MyoD antibodies. B) Graph showing percentage MyoD+ myoblasts at day 2 of 
differentiation. Red outlined circles represent nuclei. Green arrow shows MyoD+ cells.  Scale bar 50 µm. N = 6, 







3.3.9 Collagen IV increases CD9 expression in differentiating C2C12 myoblasts 
In order to gain insight into the mechanism by which collagen IV may be mediating its effect 
on myogenesis, we analysed CD9 expression in differentiating C2C12 cells cultured in the 
presence or absence of 25 µg/ml collagen IV. In response to collagen IV, CD9 expression was 
observed to visibly increase when cells were differentiated at both day 1 and day 5 (Figure 
3.9A) Densitometric analysis of CD9 expression revealed that at day 1 of differentiation, CD9 
expression increased in response to collagen IV by 93% from 100% to 193% relative to control 
(p = 0.073; Figure 3.9B). This increase was maintained and by day 5 of differentiation, CD9 
expression levels were significantly higher in cells cultured on collagen IV (145%) compared 
to control (100%) (p < 0.05; Figure 3.9B).  
 
Figure 3.9: C2C12 CD9 expression in response to collagen IV and differentiation cues.  C2C12 myoblasts 
were plated in growth media on collagen IV-coated plates or glass coverslips (0 and 25 µg/ml) and allowed to 
reach 70% confluence. Cells were then induced to differentiate for 1 or 5 days prior to fixation or lysate 
preparation. A) Representative images of C2C12 cells showing CD9 expression (white arrows) and nuclei. B) 
Graph showing CD9 expression levels (normalized to internal loading control) in C2C12 cells differentiated (day 
1 and day 5) on 0 or 25 µg/ml collagen IV. Alpha-tubulin (55 kDa) was utilized as the loading control. Confocal 
images show CD9 expression and localization. Blots were assessed by ImageJ image analysis software. Scale bar 





3.3.10 CD9 mediates fusion in response to Collagen IV 
To determine whether there is a direct relationship between the observed increased fusion and 
the up-regulated CD9 expression in response to collagen IV, we used monoclonal antibodies to 
block CD9 on differentiating C2C12 cells cultured in the presence and absence of collagen IV. 
Blocking CD9 using a monoclonal anti-CD9 antibody (at 10 µg/ml) has been previously shown 
to inhibit C2C12 fusion in vitro in the absence of collagen IV (Tachibana and Hemler, 1999). 
A range of monoclonal anti-CD9 antibody concentrations was utilized and fusion was analyzed 
at day 7. We observed that, at the highest dilution (1/1600; 0.313 µg/ml), fusion levels were 
similar to the paired control cultured in the absence of anti-CD9 antibody (Figure 3.10A,B). 
However, at a dilution of 1/800 (0.625 µg/ml), fusion in cells cultured in the absence of 
collagen IV was much lower (± 50% decrease) than in those cells differentiated in the presence 
of the matrix factor (Figure 3.10C). At a dilution of 1/400 (1.25 µg/ml), fusion was all but 
absent in cells cultured on plastic, while some fusion was still evident in cells cultured on 
collagen IV (Figure 3.10D). At a dilution of 1/200 (2.5 µg/ml) fusion was completely inhibited 
in collagen IV-coated and non-coated samples (Figure 3.10E). 
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Figure 3.10: Collagen IV treated C2C12 myoblasts are more resistant to disruption of differentiation by 
blocking of CD9. C2C12 myoblasts were plated in growth media on 0 or 25 µg/ml collagen IV-coated wells of a 
96 well plate and allowed to reach 70% confluence. Cells were then induced to differentiate for 7 days. A-E: 
Differentiating cells were incubated in the presence of varying dilutions of anti-CD9 monoclonal antibody as 





Satellite cells exist in a niche between the sarcolemma and basal lamina of skeletal muscle 
tissue (Grefte et al., 2012, Mauro, 1961). The basal lamina of skeletal muscle is a complex 
mixture of ECM and growth factors, with major components being the proteins laminin and 
collagen IV (Pallafacchina et al., 2010). In this study, we attempted to mimic aspects of the 
satellite cell niche environment by culturing C2C12 cells on exogenous ECM components 
found in the basal lamina. The effect of these factors on differentiation was assessed. 
 
Matrigel significantly increased fusion of C2C12 cells at day 5 of differentiation, with 60 
µg/ml having the greatest effect. This result was expected as Matrigel has previously been 
shown to increase the fusion of myoblasts (Grefte et al., 2012). Matrigel, even in its growth 
factor reduced form, is an extremely complex mixture of proteins and growth factors (Yu and 
Machesky, 2012). In an effort to understand which component was responsible for the effect 
on fusion, we examined the effects of the main constituents of Matrigel, namely laminin (± 
60%) and collagen IV (± 30%), on the differentiation and fusion of C2C12 cells.  
 
Laminin (6.25, 12.5 and 25 µg/ml) did not significantly affect the terminal differentiation of 
C2C12 cells. This is in agreement with results from Grossi et al (2007) and leads us to believe 
that this constituent of the basal lamina does not contribute to the increased fusion seen in 
response to Matrigel. Collagen IV however, at a concentration of 25 µg/ml, was observed to 
significantly increase fusion at day 5 of differentiation. It was also able to significantly increase 
the percentage MyoD+ cells when compared to untreated controls. Matrigel is composed of 
approximately 30% collagen IV, which translates to approximately 20 µg/ml of collagen IV in 
a 60 µg/ml Matrigel solution (Yu and Machesky, 2012). The observed increase in MyoD+ cells 
at day 2 of differentiation suggests an increase in the pool of cells that have committed to 
differentiate. This finding is supported by the recent work of Ito et al (2015) who showed that 
collagen IV significantly promoted fusion and contractibility of C2C12 IGF-1 gene engineered 
myoblasts under electrical stimulation (Ito et al., 2015). Therefore, the pro-myogenic effects of 
Matrigel may, in part, be mediated by collagen IV via a MyoD dependent pathway. The role of 
MyoD in the pathway could be confirmed by performing MyoD knock-down studies using 
RNAi. This would allow us to selectively reduce MyoD expression in the presence of collagen 
IV and quantify the effect of terminal fusion. 
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We next analysed the role of CD9 in mediating the collagen IV-stimulated increase in C2C12 
fusion. The CD9 cell surface glycoprotein is found on C2C12 cells and has been shown to be 
vital in the normal development of skeletal muscle (Tachibana and Hemler, 1999, Charrin et al., 
2013). CD9 expression is also upregulated in the early stages of C2C12 differentiation and 
blocking CD9 using monoclonal antibodies substantially delays conversion of C2C12 cells to 
elongated myotubes (Tachibana and Hemler, 1999, Charrin et al., 2013). Collagen IV could 
possibly be increasing downstream fusion of C2C12 myoblasts via an interaction with the CD9 
cell surface receptor. We therefore analysed the expression of CD9 in differentiating C2C12 
cells cultured on collagen IV. Our results indicate increased CD9 expression in C2C12 cells 
exposed to collagen IV. Although collagen IV has been observed to increase CD9 expression 
and induce cell migration through CD9 in MDA-MB-231 cells in vivo, this has not been 
previously shown in myoblasts (Castro-Sanchez et al., 2010). The observed increase began at 
day 1 of differentiation and was maintained to significant levels by day 5 of differentiation. 
Furthermore, blocking of CD9 using a monoclonal antibody at a concentration of 1.25 µg/ml 
almost completely abrogated differentiation of C2C12 cells in the absence of collagen IV; 
collagen IV-treated samples however showed low levels of fusion in the presence of the same 
concentration of anti-CD9 antibodies. This may be due to an upregulation of cell surface CD9 
when cultured on collagen IV and lack of sufficient anti-CD9 antibodies to block the increased 
number of CD9 receptors, leaving some CD9 molecules free to maintain a differentiation 
potential. This is supported by the observation that, at a higher antibody concentration (Figure 
3.11) (2.5 µg/ml) fusion was completely blocked in cells cultured on collagen IV, whereas at a 
lower concentration (0.625 µg/ml) differentiation was restored to cells differentiated on 
collagen IV coated plates when compared to controls (Figure 3.11). Our findings are supported 
by the study of Tachibana and Hemler (1999); they observed that anti-CD9 antibodies inhibited 
C2C12 cell differentiation. This was not a non-specific effect, as use of an isotype control in 
the study did not similarly decrease differentiation (Tachibana and Hemler, 1999). These 
results support the premise that the increase in differentiation observed when C2C12 myoblasts 
are cultured on Matrigel is due to a collagen IV/CD9-dependent mechanism. It also emphasizes 




Figure 3.11: Schematic representation of CD9 blocking. The upregulation of CD9, when cells are cultured on 
collagen IV coated plates, makes them more “resistant” to blocking with anti-CD9 antibodies. At an antibody 
dilution of 1/1600, both collagen IV and control samples have free CD9 sites; differentiation is therefore observed 
in both. At 1/800 and 1/400, cells cultured on collagen IV have some CD9 sites free and this allows some 
differentiation to proceed. However, in control samples, CD9 expression is not upregulated and all endogenous 
sites are blocked resulting is disrupted differentiation. At a dilution of 1/200, the antibody is in excess and blocks 




In summary, we have shown, for the first time, that the collagen IV-mediated increase in 
terminal differentiation of myoblasts is mediated, at least in part, by CD9. This suggests that 
extracellular matrix factors do not only signal via integrins and presents an additional 






























COLLAGEN IV MODULATES THE DOSE-DEPENDENT EFFECT OF HGF ON 
C2C12 MYOGENESIS  
 
Extracellular matrix (ECM) and growth factors are known to have complex 
interactions that may modulate their activity in vivo. We have previously shown that 
HGF regulates myogenesis in a dose-dependent manner. Furthermore, we showed that 
components of the basal lamina, such as collagen IV, also regulate myogenesis. In the 
current study we aimed to determine whether collagen IV mediates the dose dependent 
effect of HGF on myogenesis. Murine C2C12 myoblasts were cultured on collagen IV, 
in the presence or absence of HGF, and differentiation and proliferation assessed. 
Collagen IV was not able to negate the negative effect of HGF (2 ng/ml) on fusion, but 
was able to restore normal MyHC expression. Collagen IV did not alter the pro-
myogenic effect of 10 ng/ml HGF. Under proliferative conditions, collagen IV alone was 
unable to affect C2C12 cell numbers, cell viability or CD9 expression. Furthermore, 
collagen IV was observed to be unable to modulate the previously reported dose-
dependent effects of HGF on C2C12 cell numbers. Due to a collagen IV stimulated 
increase in CD9 expression in differentiating myoblasts, cells cultured on collagen IV 
required higher levels of neutralizing anti-CD9 monoclonal antibodies to reduce fusion; 
an effect not observed when cells were differentiated in the presence of HGF alone. In 
HGF (10 ng/ml) treated samples, fusion was completely inhibited when CD9 was 
completely blocked suggesting that CD9 is a crucial co-factor in HGF (10 ng/ml)-
induced fusion. These results show, for the first time, that despite the proliferative 
effect of low concentrations of HGF, collagen IV still promoted myogenic regulatory 
factor expression and early differentiation. The interactive effects of collagen IV and 
HGF are confirmed to be mediated by CD9, but there may be an upper limit to the 










In vivo, the extracellular stimuli that a satellite cell is exposed to, is a lot more complex than 
our single ECM factor studies can simulate. In healthy, uninjured muscle, the satellite cell 
resides in quiescence in its collagen IV and laminin rich niche between the basal lamina and 
sarcolemma of the muscle fiber (Sanes, 2003). Upon injury, HGF stimulates the satellite cell 
to become active before migrating out of its niche towards the site of injury which is 
characterized by ECM factors such as fibronectin and collagen I. Therefore the cell is in 
constant contact with a multitude of external ECM components and the composition and 
concentration of the satellite cell ECM changes as the cell progresses through myogenesis 
during repair.  
 
In the previous chapters we examined the effects of extracellular matrix proteins such as 
HGF, collagen IV and laminin on C2C12 differentiation and proliferation. We found that 
HGF (2 ng/ml) significantly promoted cell division, but reduced myogenic commitment and 
fusion. Conversely, 10 ng/ml HGF reduced proliferative capability, but increased 
differentiation. We then determined that collagen IV, and not laminin, positively regulated 
differentiation of C2C12 cells; cells cultured on 25 µg/ml collagen IV showed a significant 
increase in fusion at day 5 when compared to cells cultured on uncoated tissue culture plates. 
This was accompanied by an increase in CD9 expression; neutralizing antibody studies 
further suggested a potential role for CD9 in mediating the observed increase in fusion. 
 
ECM and growth factors are known to have complex interactions with each other and with 
growth factors. Combined ECM experiments often show synergistic effects of the individual 
ECM components. For instance, fibronectin and laminin individually have been shown to 
increase the differentiation of adult neural stem cells and their combination enhances this 
increase (Cooke et al., 2010). Decorin has been shown to modulate collagen I, but not 
fibronectin stimulated migration of C2C12 cells in vitro (Goetsch et al., 2011). Furthermore, 
collagen I and decorin were shown to have a physical interaction via separate core protein-
binding domains (Schonherr et al., 1995). Previously, Collagen IV has been shown to 
interact with a range of ECM factors including laminin, fibronectin and decorin and is vital 
for basement membrane stability (Poschl et al., 2004, Aumailley and Timpl, 1986, Charonis 
et al., 1985, Leppert et al., 2000). Interestingly, collagen IV has also been shown to bind 
HGF with a mild affinity (Schuppan et al., 1998). Reversible binding of HGF to immobilized 
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collagen IV has been reported to result in a collagen-HGF complex that is able to induce 
primary hepatocyte proliferation in a dose-dependent manner. Further investigation revealed 
that binding was due to specific peptide sequences unique to collagenous proteins suggesting 
a specific role for collagens in HGF bioavailability and activity (Schuppan et al., 1998). It 
therefore becomes important to investigate combinations of ECM and growth factors to 
mimic the in vivo environment more closely and thereby more fully understand how, 
together, these proteins modulate cell behavior. At this stage, very little is known about the 
effect of collagen IV in mediating HGF signaling in myoblasts. 
 
In this study, the effects of collagen IV on the previously observed dose-dependent effect of 
HGF on C2C12 myogenesis was examined. Terminal differentiation and proliferation were 
evaluated and we attempt to uncover the mechanisms at play by examining transcription 























4.2 Materials and methods: 
 
All reagents were of an analytical grade and obtained from Sigma-Aldrich (USA), unless 
stated otherwise. All cell culture was performed under sterile conditions in a level II 
biological safety cabinet (ESCO Class II BSC). 
 
4.2.1 Cell Culture 
 
The C2C12 murine cell line was purchased from the American Type Culture Collection 
(ATTC, CRL-1772). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (Highveld 
Biological, CN3193-9) supplemented with 10% (v/v) Fetal Bovine Serum (Biowest, S181H-
500), 2% (v/v) L-glutamine (Lonza, BE17-605E) and 2% (v/v) Penicillin-Streptomycin 
(Lonza, DE17-602E). For differentiation studies, cells were cultured to a confluence of 70% 
after which media was changed to differentiation media (DMEM supplemented with 2% 




Differentiation media consists of 485 ml DMEM, 10 ml PenStrep (2% v/v) and 5 ml horse 
serum (16050-130; Invitrogen; USA) filter sterilized prior to storage in 50 ml falcon tubes at 
4°C. When cells reached approximately 70% confluence, the media was changed to 
differentiation media. Cells were maintained at 37 °C, 5% CO2 in a humidified incubator.  
 
4.2.3 ECM Coating and HGF addition 
 
4.2.3.1 Collagen IV Coating  
Collagen IV (Human; 0.3 mg; C6745; Sigma-Aldrich; USA) was diluted to a stock solution 
of 0.1 mg/ml with sterile PBS containing 0.25% acetic acid at 4 °C. T25 culture flasks and 
24 well plates containing glass coverslips were coated with 3 ml and 500 µl of a 25 µg/ml 
collagen IV solution respectively. All plates were incubated at 37 °C for 4 hours, before the 
protein solutions were removed and the plates allowed to air dry under U.V. light overnight. 
Plates and wells are washed with sterile PBS before use and stored at 4 °C for no longer than 
a month.  
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4.2.3.2 HGF addition 
 
Active human HGF (PeproTech, cat.100-39) was used at a final concentration range of 0, 2 
and 10 ng/ml and media changed every 48 hours during differentiation studies. Cells were 
incubated at 37°C in a humidified incubator at 5% CO2. All experiments were carried out 
under sterile conditions in a Class II Biohazard Safety Cabinet.  
  
Clustal W alignments were conducted to compare the amino acid sequences of the ECM and 
growth factors used in this study and those found in mice (Mus Musculus) (Appendix III). 
Scores between 79.2899 and 88.4882 showed that proteins were highly conserved in all 
cases. 
 
4.2.4 Immunocytochemistry and Confocal Microscopy 
 
C2C12 cells were plated onto coverslips in a 24 well plate and allowed to reach 70% 
confluence in 500 µl growth media. Wells had previously been coated with the collagen IV 
as described earlier. HGF addition took place with initial plating out and at all media changes 
(day -1, 0 and 3). Differentiating (day 1, day 2 and day 5) cell samples were cultured in 
differentiating media for 24, 48 and 120 hours respectively. Coverslips were subsequently 
washed with PBS and fixed with 4% paraformaldehyde for 15 minutes. They were then 
washed with PBS and blocked using 5% donkey serum. Coverslips were then incubated with 
primary antibodies for 4 hours at room temperature: day 0: mouse monoclonal anti-CD9; day 
2: rabbit polyclonal anti-MyoD; day 5: mouse monoclonal anti-MyHC, mouse monoclonal 
anti-CD9. Coverslips were then washed 4 x 8 minutes with PBS before being incubated with 
appropriate secondary antibody for 40 minutes (Table 4.1). These were washed 3 x 8 minutes 
with PBS before being treated with Hoechst 33342 nuclear stain (Stock: 10 mg/ml; 1/4000; 
Sigma-Aldrich; USA). Coverslips were then washed for a further 4 x 8 minutes with PBS 






Table 4.1: Antibody concentrations (optimized) used in Confocal microscopy 





Rabbit polyclonal anti-MyoD (sc-760, 
Santa Cruz; USA) 
1/100 Donkey anti-rabbit Dylight 488 
  (711-455-152, Jackson ImmunoResearch) 
1/1000 
Mouse monoclonal anti-MyHC (MF-
20; DSHB; USA) 





Donkey anti-mouse Dylight 494 
 (715-515-151, Jackson ImmunoResearch) 
Donkey anti-mouse Dylight 488 




    
 
4.2.4.1 Assessment of percentage MyoD+ cells  
 
Cells shown to be expressing nuclear MyoD were counted and determined as a percentage of 
total nuclei on day 2 (percentage MyoD+) of differentiation. Images were examined using Zen 
software (Zeiss) allowing visualization of a single plane and accurate quantification. 
Approximately 20 cells per image were analysed and a minimum of 5 fields of view (i.e. 100 
cells/n), randomly selected, were used for n=1. Experiments were repeated n = 6-8 times. 
 
4.2.4.2 Assessment of terminal differentiation via a fusion index  
 
The fusion index was determined via quantitative analysis of confocal images of differentiated 
myotubes (day 5). Images were exported using Zen software (Zeiss) as a single plane with both 
the red channel (MyHC) and the blue channel (Hoechst). This allowed us to count the number 
of nuclei in fused myotubes (containing 2 or more nuclei). This number was divided by the 
total number of nuclei in the field of view and multiplied by 100. A minimum of 4 fields of 
view, randomly selected, were used for n=1. Experiments were repeated n = 6-8 times. 
 
4.2.5 Protein separation by SDS-PAGE 
 
Lysate sample preparation is outlined in Appendix IV. The Laemmli protocol was used for 
SDS-PAGE (Laemmli, 1970) with several modifications outlined in Appendix IV. The 
BioRad electrophoresis unit (BioRad; Mini-PROTEIN 3 Cell; USA) was utilized for the 
running of all polyacrylamide gels. 10% or 12.5% gels were cast between two glass plates, as 
described in the Appendix IV, and allowed to solidify (~1 hour) before the stacking gel was 
added with a 10 fingered comb to create the lanes for sample loading. Once the stacking gel 
had set (~30 minutes) the comb was gently removed and lanes washed with distilled water. 
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Electrode (tank) buffer was poured into the inner and outer electrode compartments before 
the prepared samples were loaded. The samples were prepared by adding an equal volume of 
reducing sample treatment buffer to the sample and boiling the solution for 2 minutes. 
Samples were then stored on ice until loaded. 1 µl bromophenol blue (1437500CB; 
Saarchem; RSA) was added to each sample so that the buffer front could be clearly discerned. 
25 µg of protein per lane was added to the gel as determined by the Bradford Assay 
(Appendix IV). 3 µl of the PeqGold protein marker V (27-2210; Peqlab; Germany) was run 
in at least one lane of each gel for later determination of protein molecular weights. Gels 
were run at 4 °C with 18 mA per gel until the buffer front reached the bottom of the running 
gel. The gel was removed from between the glass plates and either stained with the 
Coomassie G-250 stain or processed for western blot analysis.  
 
4.2.6 Western Blot analysis 
 
Gels were placed within a blotting sandwich made up of the following; a piece of 
nitrocellulose (Hybond-C Extra; Amersham Biosciences; UK) the same size as the gel which 
was place over the gel, two pieces of Whatman No.4 filter paper was placed on either side of 
the gel and nitrocellulose, followed by two pieces of Scotchbrite foam placed on either side 
of the filter paper. The sandwich was placed in a western blot cassette and loaded into the 
western blot apparatus (Omni Page; Cleaver Scientific Ltd; UK) containing blotting buffer. 
The nitrocellulose must be place on the positive side of the apparatus as the proteins in the 
gel are negatively charged. The blot was run in the fridge (4 °C) at 400 mA for 4 hours or 60 
mA for 16 hours (Appendix V).  
 
The nitrocellulose was then removed and the gel placed in Coomassie G-250 stain to 
determine whether total protein transfer had occurred. The nitrocellulose was placed in the 
Ponceau S. stain (2 minutes) and destained with TBST until clear bands were visible. This 
gave an indication of whether the protein transfer was performed correctly and equal loading 
had been achieved. The nitrocellulose was washed a further two times in TBST to remove 
the remaining Ponceau S. stain. The nitrocellulose was then blocked in 5% (m/v) low fat 
milk powder (made up in TBST) for 1 hour. Primary antibody (Table 4.2) made up in TBST 
was then added to the nitrocellulose for 2 hours. This was followed by wash steps with 
TBST (4 x 8 minutes). All wash steps were performed with vigorous agitation. HRPO-linked 
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secondary antibody made up in TBST was then added for 1 hour. This was followed by 
washing with TBST (6 x 8 minutes).  
Table 4.2: Antibody concentrations used in Western blot 




    
Mouse monoclonal anti-MyHC (MF-
20; DSHB; USA) 





Donkey anti-mouse IgG  
(ab96857, Abcam; UK) 
Donkey anti-mouse IgG  




     
  
Enhanced Chemiluminescence (ECL) technique was used for the development of the bands. 
All steps of ECL which involves the use of the light film (Kodak BioMax light film; 
Z370398; Sigma-Aldrich; USA) were performed in the dark room with no white light 
present. The substrate was made by adding peroxide and enhancer solutions in a 1:1 ratio 
(Immun-Star WesternC; 70-5070; Bio-Rad, USA). The substrate (1 ml) was added to the 
nitrocellulose for 2 minutes. The nitrocellulose was placed between two pieces of transparent 
film and the position of the molecular weight markers were indicated on the transparent film 
for easy identification in the dark room. Prior to development, the developer (Structurix 
G128; Agfa; 5TBN; Belgium) and the fixative (G333c Rapid Fixer; Agfa; EGCQT; 
Belgium) solutions were made up with water in a 1 in 4 dilution and a 1 in 3 dilution, 
respectively. A piece of light film was cut to the same size as the nitrocellulose and placed 
over the nitrocellulose located between the transparency sandwich. The light film was left on 
the nitrocellulose for up to 10 minutes depending on the antibodies being used. The film was 
placed in the developer solution until the bands developed (~5 minutes) and then placed in 




The bands that developed on the film were analyzed by use of computer software (Image J, 
http://imagej.nih.gov/ij/). Densitometric analysis was selected and the background was 




3.2.7 Monoclonal antibody blocking 
 
C2C12 myoblasts (15 000 cells/well) were plated in collagen IV-coated and non-coated 
wells of a flat-bottom 96 well culture plate (Corning, CR/3596) and allowed to reach 70% 
confluence. Media was then replaced with diffferentiation media containing mouse 
monoclonal anti-CD9 (BD 551808, USA; 0, 1/1600, 1/800, 1/1600 dilution) and allowed to 
differentiate for 7 days. Media (containing various dilutions of mAbs) was replaced every 2 
days.  
 
4.2.8 Statistical analysis 
 
The results from each experiment were expressed as a Mean ± SEM. The student’s t-test was 
performed on all data. Samples were considered to be statistically significant if they 
























4.3.1 Collagen IV mediates HGF-modulated C2C12 differentiation 
We previously reported that HGF (2 ng/ml) significantly inhibited fusion and MyHC 
expression in day 5 differentiating C2C12 cells (Section 2.3.1). To determine whether 
collagen IV modifies the effect of HGF on C2C12 fusion and MyHC expression, cells were 
cultured and differentiated on collagen IV (25 µg/ml) coated coverslips (for fusion index 
assessment) or flasks (for Western blotting) in media supplemented with HGF (0, 2 and 10 
ng/ml). In the presence of collagen IV, HGF (2 ng/ml) was observed to still reduce the 
number of fused myotubes, whereas HGF (10 ng/ml) did not elicit the previously reported 
increase in myotube fusion (Figure 4.1A). Calculation of percentage fusion revealed that 2 
ng/ml HGF significantly (p < 0.05) reduced terminal fusion at day 5 in cells cultured on 
collagen IV when compared to the collagen IV coated control (HGF 0 ng/ml) from 50 ± 3% 
to 38 ± 5% (Figure 4.1B). However, the addition of the HGF (10 ng/ml) to collagen IV did 
not significantly increase fusion when compared to collagen IV alone (Figure 4.1B). HGF, at 
either dose was however unable to significantly alter MyHC expression in the presence of 
collagen IV, when compared to cells cultured on collagen IV in the absence of HGF (Figure 
4.1C). This suggests that although collagen IV can restore normal MyHC expression to 
C2C12 cells treated with 2 ng/ml HGF, it is unable to restore normal levels of fusion. 
Furthermore, collagen IV abolished the ability of HGF (10 ng/ml) to promote fusion or 


















































4.3.2 Collagen IV prevents the dose-dependent effect of HGF on MyoD expression 
We previously reported (Kahamba, 2013), Walker et al., 2015) that HGF may mediate its 
dose-dependent effect via MyoD. To determine the effect of collagen IV on the HGF-
mediated change in percentage MyoD+ cells, myoblasts were cultured and induced to 
differentiate on collagen IV (25 µg/ml) coated plates in media supplemented with HGF (0, 2 
and 10 ng/ml) for 2 days. HGF at either dose was unable to significantly alter percentage 
MyoD+ cell numbers (HGF 2 ng/ml = 42 ± 6%; HGF 10 ng/ml = 44 ± 7%) in the presence of 
collagen IV, when compared to samples coated on collagen IV alone (46 ± 3%; Figure 4.2A, 
B). These results suggest that collagen IV (25 µg/ml) prevents HGF from significantly 
affecting the percentage MyoD+ in differentiating C2C12 cells.  
 
Figure 4.2: HGF, in the presence of collagen IV, does not modulate percentage MyoD+ C2C12 myoblasts. 
C2C12 myoblasts were plated in HGF supplemented growth media on coated glass coverslips and allowed to 
reach 70% confluence. Cells were then induced to differentiate for 2 days prior to fixation and immunostaining 
for MyoD. A) Representative images showing MyoD+ cells. B) Percentage MyoD+ cells. Red outlined circles 
represent nuclei.  Green arrow shows MyoD+ cells.  Scale bar = 20 µm. Data represents 6 independent 
experimental repeats. Data is presented as mean ± SEM.  
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4.3.3 HGF treated C2C12 cell differentiation is not more resistant to CD9 blocking than 
control samples 
Blocking CD9 using an anti-CD9 monoclonal antibody has been shown to inhibit C2C12 
fusion in vitro (Tachibana and Hemler, 1999). We showed in the previous chapter that C2C12 
cells differentiated on collagen IV increase their CD9 expression and appear more resistant to 
the negative effect of CD9 neutralizing antibodies on fusion. In an effort to understand whether 
CD9 plays a role in mediating the negative effect of collagen IV on HGF (10 ng/ml)-mediated 
differentiation, we cultured cells on collagen IV in the presence or absence of HGF (10 ng/ml) 
as well as HGF (10 ng/ml) alone, and assessed the effect of anti-CD9 antibodies on 
differentiation. At a dilution of 1/1600 (0.313 µg/ml), fusion was similar to control conditions 
(no antibody) in all samples treated (Figure 4.3). However, at a concentration of 1/800 (0.625 
µg/ml), a reduction in fusion was observed in all groups with a greater reduction in HGF 
samples (compared to collagen IV and collagen IV + HGF samples) (Figure 4.3). Interestingly, 
we observed that HGF-mediated fusion was completely abrogated at an antibody dilution of 
1/400 (1.25 µg/ml) in cells cultured in the absence of collagen IV while cellular fusion, albeit 
in very low levels, was observed in the presence collagen IV and collagen IV + HGF samples 



















































Figure 4.5: HGF treated C2C12 myoblasts are not more resistant to disruption of differentiation by blocking of CD9. 
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4.3.4 Collagen IV does not significantly affect C2C12 myoblast proliferation, viability or 
CD9 expression 
Given the ability of collagen IV to modulate the effects of HGF on differentiation, we next 
tested whether collagen IV also plays a key role in regulating myoblast proliferation. C2C12 
cells (10 x 104 cells/plate) were cultured on collagen IV (0, 25 µg/ml) coated plates and cell 
number and viability assessed after 24 hours. Cell number and viability were not significantly 
affected in response to collagen IV (Figure 4.4A and B). Cell numbers at 24 hours were 24,9 x 
104 under control conditions and 25,3 x 104 when cultured on collagen IV. Confocal analysis 
revealed similar levels of CD9 expression (Figure 4.4C) and although CD9 expression was 
previously observed to increase in differentiating C2C12 cells (Section 3.3.7), no significant 
change in CD9 expression was observed in response to collagen IV under proliferative 
conditions (Figure 4.4D). These results suggest that differentiation cues may be required in 















































4.3.5 Collagen IV does not modulate the dose-dependent effect of HGF on proliferation 
To determine whether collagen IV modifies the dose-dependent effect of HGF on C2C12 
cell number, cells were cultured on collagen IV (25 µg/ml) in media supplemented with HGF 
(0, 2 and 10 ng/ml). In the presence of collagen IV, HGF (2 ng/ml) stimulated the 
characteristic increase in proliferation, whereas incubation with HGF (10 ng/ml) caused the 
expected reduction in cell number (Figure 4.5A). Cell counts revealed a significant 29% 
increase from 30 x 104 cells to 46 x 104 cells (Figure 4.5A; p < 0.05) in response to 2 ng/ml 
HGF in combination with 25 µg/ml collagen IV when compared to cell counts conducted on 
samples cultured in the absence of HGF. Following incubation with 10 ng/ml HGF in 
combination with 25 µg/ml collagen IV a significant 37% reduction in cell numbers was 
observed from 30 x 104 cells to 19 x 104 cells (Figure 4.5A; p < 0.05) when compared to cell 
counts conducted on samples cultured in the absence of HGF. The percentage viability was 
also not affected and remained at previously reported (section 2.3.4) levels of approximately 
85-90% (Figure 4.5B). 
 
Figure 4.5: Collagen IV does not alter the dose-dependent effect of HGF on C2C12 proliferation. C2C12 
myoblasts were plated in HGF supplemented growth media in coated flasks and allowed to reach 70% 
confluence. Cell numbers were determined using the BioRad TC-20 cell counter and trypan blue. A) Total cell 
numbers. B) Viable cell numbers. Dashed line represents initial cell number seeded, flasks were seeded with 10 





We previously reported that HGF (2 ng/ml) inhibited C2C12 MyHC expression and fusion, 
while 10 ng/ml HGF promoted MyHC expression and fusion (Walker et al., 2015). 
Furthermore we subsequently showed that collagen IV, a major component of the basal lamina 
of the satellite cell niche, is able to promote myogenesis (Walker & Niesler, 2015; submitted). 
In the current chapter we determined whether collagen IV can modulate the previously 
reported dose-dependent effects of HGF on C2C12 myoblasts. Our results revealed that 
although collagen IV (25 µg/ml) did not negate the negative effect of HGF (2 ng/ml) on fusion, 
it did restore normal MyHC expression. This leads us to believe that HGF (2 ng/ml) may 
negatively regulate C2C12 differentiation via at least two mechanisms; 1) inhibition of cell-
specific contractile protein expression (reversible by collagen IV) and 2) prevention of the later 
stages of fusion (not reversible by collagen IV exposure). On the other hand, in the presence of 
collagen IV (25 µg/ml), HGF (10 ng/ml) was not able to stimulate an increase in fusion and 
MyHC expression over and above collagen IV levels suggesting that maximum C2C12 in vitro 
fusion has been reached or that HGF and collagen IV mediate their pro-myogenic effects via a 
common pathway.  
 
In order to begin delineating the role of CD9 in mediating collagen IV and HGF-mediated 
differentiation, CD9 neutralizing antibodies were used at a dilution range from 1/400 to 1/1600. 
Following blocking of CD9 using a monoclonal antibody at a dilution of 1/1600, normal fusion 
was observed in all samples treated. However, at a dilution of 1/800, collagen IV-treated 
samples were more “resistant” to the inhibitory effect of the CD9 neutralizing antibodies when 
compared to samples treated with HGF (10 ng/ml) alone. In addition to this, we observed that 
fusion was completely abrogated at a dilution of 1/400 for samples treated with HGF (10 
ng/ml) while fusion, albeit in very low levels, is present in samples treated with collagen IV. 
This may be due to an upregulation of CD9 when cultured on collagen IV and lack of sufficient 
anti-CD9 antibodies to fully block this increase, leaving some CD9 molecules free to maintain 
a differentiation potential. Alternatively, the presence of fusion in collagen IV samples when 
treated with a dilution of 1/400 anti-CD9 antibodies may suggest that although all CD9 sited 
are blocked, collagen IV may also induce C2C12 differentiation via a CD9 independent 
pathway as well as increasing CD9 cell surface expression. In addition to CD9, collagen IV is 
known to bind to cell surface receptors knows as integrins (Leitinger and Hohenester, 2007). 
Integrins are the major transmembrane receptors involved in cell adhesion to the ECM 
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(Humphries et al., 2006). Integrins interact with the ECM and assist in signaling and cell-fate 
determination, and it is through these interactions that the ECM is believed to influence 
myogenesis and could account for the increased increase in fusion (Hynes et al., 2002). This 
however, requires further investigation. 
 
Anti-CD9 antibodies were able to block HGF-stimulated fusion at high dilutions. This suggests 
that the previously documented pro-myogenic effects of HGF on fusion (Walker et al., 2015) 
may be due to a CD9-dependent pathway, however it is necessary to detect the expression of 
CD9 in response to HGF. A lack of increased CD9 expression would explain the inhibition of 
fusion at higher antibody dilutions.  This hypothesis is supported by findings that knocking 
down CD9 expression significantly inhibited the well-documented effects of VEGF and HGF 
on endothelial cell motility and invasion in vitro (Kamisasanuki et al., 2011). Furthermore, in 
vivo studies show that knocking down CD9 expression with siRNA inhibited HGF- and 
VEGF-induced subconjunctival angiogenesis (Kamisasanuki et al., 2011). Other studies 
reinforce a specific requirement for CD9 in HGF signaling; an M.S. study from Michigan State 
University determined that CD9 is required for CD82 suppression of HGF-induced Met 
activation (Spotts, 2010).  
 
In response to collagen IV, C2C12 proliferation and viability were not observed to be 
affected; CD9 expression was also not significantly altered under proliferative conditions. It 
may be worthwhile to analyze CD9 expression levels following 48 hours of proliferative 
culture on collagen IV to determine whether extended incubation is required to stimulate 
changed in CD9 expression levels. HGF has been reported to demonstrate a dose-dependent 
effect on C2C12 proliferation. HGF (2 ng/ml) was observed to significantly increase C2C12 
proliferation with 10 ng/ml HGF having the opposite effect and significantly inhibiting 
differentiation (Walker et al., 2015). Combination studies revealed that collagen IV was 
unable to regulate the previously reported effects of HGF on proliferation of C2C12 
myoblasts. 
 
In summary, we demonstrated that collagen IV, along with being a positive modulator of 
myogenesis, can also mediate the dose-dependent effects of HGF on myogenesis. This 
demonstrates the ability for the ECM to affect the action of growth factors and highlights the 
need to consider ECM-growth factor interactions during in vitro studies. 
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CHAPTER 5: DISCUSSION 
 
 
Undifferentiated C2C12 cells are a mouse myoblast cell line capable of differentiation and 
fusion into myotubes, making them an ideal model for skeletal muscle repair studies in vitro. 
We attempted to examine the effects of a range of ECM and growth factors on various 
aspects of myogenesis.  
 
HGF is a growth factor that has been shown to be vital in the activation of satellite cells during 
early stages of myogenesis. We differentiated C2C12 cells in media supplemented with HGF 
and noted a dose dependent effect of this supplementation. At low concentrations (2 ng/ml) 
differentiation was impaired, but at higher concentrations (10 ng/ml) this effect was the 
opposite and fusion was in fact promoted. However, with regard to proliferation, 2 ng/ml HGF 
significantly increased cell numbers, while 10 ng/ml significantly reduced them when 
compared to untreated controls. This result suggests a dual mechanism of HGF on myoblasts 
during proliferation and differentiation. In an attempt to understand the mechanisms at play, we 
examined the expression levels of the c-Met receptor in response to treatment with HGF. 
Changes in c-Met receptor expression levels were noted in response to HGF and the dose 
dependent effects of the growth factor on proliferation and differentiation could be correlated 
directly to expression levels of this receptor. Grp2 and p85 are two distinct mediators of the 
effect that HGF can have on differentiation. Grp2 signals via the Ras pathway, which reduces 
myoblast differentiation and signaling via the p85 mediator results in signaling via the 
phosphatidylinositol 3-kinase (PI3K) pathway that induces cell differentiation (Leshem et al., 
2002).  Although our results suggest that PI3K and p38 mediate the anti-proliferative effect of 
HGF at higher concentrations, the pro-proliferative mechanism is still unclear and may be 
related to changes in adaptor protein association (such as Grb2) at the cell membrane. 
 
Matrigel, even in its growth-reduced form, is a complex mixture of over 1000 ECM proteins 
and growth factors (Hughes et al., 2010, Kohen et al., 2009). Matrigel was observed to 
increase terminal fusion in C2C12 myoblasts. However, it is difficult to interpret this result, 
as Matrigel is comprised of numerous proteins and growth factors. In an attempt to 
determine which portion of Matrigel was responsible for this result, we differentiated C2C12 
cells on the major components of Matrigel, laminin and collagen IV. We used a subtype of 
laminin, laminin-111 in our studies, which is the major laminin component Matrigel 
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(Neubauer et al., 2009). This laminin does however differ in its alpha domain from the 
laminin found in the skeletal muscle basal lamina, which is laminin-211 (Holmberg and 
Durbeej, 2013). We proceeded with laminin-111 because of its relevance to the earlier 
Matrigel study and due to the fact that laminin interacts with collagen through its beta 
domain, which is identical on both subtypes in this study (Kleinman et al., 1987). We found 
that laminin-111 alone had no effect on C2C12 differentiation. It would however be 
important to investigate laminin-211 in similar studies in the future, as it is the subtype found 
in the basal lamina of skeletal muscle. We then differentiated C2C12 cells on collagen IV, 
the second largest constituent of Matrigel. Here, we observed that collagen IV increased 
fusion similarly to the Matrigel-induced fusion observed. Collagen IV also increased the 
percentage of MyoD+ cells. This suggests that these cells were committed to differentiate and 
that fusion levels may have been more substantially increased by collagen IV over a longer 
time frame. This result led us to believe that the positive effect on fusion displayed by 
Matrigel was, at least in part, due to its second largest constituent, collagen IV.  
 
Collagen IV has been shown to interact with the CD9 receptor; blocking the CD9 receptor on 
C2C12 cells has been shown to reduce their fusion in vitro (Tachibana and Hemler, 1999, 
Charrin et al., 2013). Collagen IV may therefore interact with the CD9 receptor to increase 
myoblast fusion.  Assessment of CD9 expression on C2C12 cells cultured in absence and 
presence of collagen IV exposed a possible mechanism for our findings; CD9 expression is 
elevated at day 1 and day 5 of differentiation in response to collagen IV. Blocking of CD9 
(with monoclonal antibodies raised against CD9) further supported this finding with 
differentiation of C2C12 cells cultured on collagen IV more resistant to the inhibitory effects 
of these neutralizing antibodies. Assessment of MyoD at earlier time points (day 1), as well 
as myogenin, could lead to additional insight into the mechanism at play. Collagen IV was 
not observed to have a significant effect on C2C12 cell number, viability or CD9 expression 
under proliferative conditions. 
 
In an attempt to more closely mimic in vivo conditions, we then supplemented C2C12 cells 
differentiating on collagen IV with HGF.  Interestingly, collagen IV did not prevent lower 
concentrations of HGF (2 ng/ml) from inhibiting differentiation; however it was able to 
restore normal levels of MyHC, suggesting that 2 ng/ml HGF may be inhibiting the final 
stages of fusion, but not the earlier stages characteristic of myogenic progression. This was 
supported by the normal levels of MyoD in samples treated with collagen IV and HGF (day 
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1). Higher concentrations of HGF (10 ng/ml) did not increase collagen IV-induced fusion 
suggesting that these components do not have a synergistic or additive effect on myogenesis. 
 
Blocking of CD9 with monoclonal antibodies raised against CD9 in samples treated with 
HGF (10 ng/ml) and cultured on collagen IV exposed the possibility that collagen IV may be 
producing its pro-myogenic effect on C2C12 cells by numerous mechanisms. This is 
suggested as although fusion was reduced in samples blocked with a dilution of 1/400 anti-
CD9 antibodies, it was not completely abolished. This was in contrast to samples treated 
with HGF (10 ng/ml) where a dilution of 1/400 anti-CD9 antibodies completely abrogated all 
fusion. This suggests that CD9 activity is required for successful HGF signaling, which is in 
agreement with previously published results (Kamisasanuki et al., 2011, Spotts, 2010). 
Analysis of CD9 expression levels in response to HGF is necessary before drawing further 
conclusions. 
 
Interestingly, collagen IV was unable to modulate the dose-dependent effects of HGF on 
proliferation. This may be attributed to the fact that CD9 levels are not significantly elevated 
in proliferating C2C12 cells cultured on collagen IV suggesting a different mechanism at 




1. HGF has a dose-dependent dual role in myogenesis. Our results suggest that PI3K 
and p38 mediate the anti-proliferative effect of HGF at higher concentrations, 
however the pro-proliferative mechanism of 2 ng/ml HGF is still unclear. 
2. Collagen IV promotes myogenesis in part through an increase in CD9 expression, 
however, multiple mechanisms may be at play. 
3. Collagen IV is able to modulate the negative effect of HGF (2 ng/ml) on C2C12 
MyHC expression, but is unable to restore adequate fusion.  
4. Collagen IV does not to modulate the dose-dependent dual role of HGF on C2C12 
proliferation. 







1. Analysis of fusion proteins such as kirrel, nephrin WAVE and nap1 would be 
valuable in understanding the effects of low doses of HGF on fusion (Kestila et al., 
1998, Richardson et al., 2007, Strunkelnberg et al., 2001).  
 
2. Including analysis of the effect of collagen I and fibronectin (major components of 
fibrotic scar tissue found in extreme muscle injury) on myogenesis would further our 
understanding into the role of the ECM in fibrosis and wound repair. 
 
3. Finally, although 2D monolayer cell culture studies provide tremendous insight into 
the role of ECM factors in myogenesis, investigations must be extended to 3D 
bioengineered tissue. This will provide information as to the role of the ECM factors 
























Supplementary Figure 1: Effect of Dimethyl Sulfoxide (DMSO) on C2C12 cell viability. Viability of 
proliferating C2C12 myoblasts incubated in growth media containing either 0.04% or 0.01% DMSO was 
assessed at 24h. 100 000 C2C12 myoblasts were initially seeded and analysis performed using the TC20 
automated cell counter (BioRad) for 3 independent experimental repeats, each in duplicate. Data is presented as 
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Postgraduate Research Day, Faculty of Science & Agriculture, UKZN, 2012 
 
EFFECT OF GROWTH AND EXTRACELLULAR MATRIX FACTORS ON 




School of Life Sciences 
Supervised by Dr Carola Niesler 
 
 
Satellite cells are muscle stem cells that reside between the myolemma and the 
sarcolemma of mature muscle fibers. These cells are the means of cellular muscle 
repair and are activated to myoblasts upon muscle damage to proliferate and 
differentiate into myotubes. Differentiated myotubes fuse to existing muscle fibers with 
in situ necrotic muscle injury allowing full muscle repair. With shear-type injuries 
these myotubes fuse to fibrotic scar tissue in the wound and full muscle regeneration is 
not possible. ECM factors in the satellite cell niche maintain and regulate aspects of 
quiescence, activation, proliferation and differentiation. Following muscle injury, 
growth factors and interstitial extracellular matrix (ECM) factors direct the process of 
muscle regeneration and self-renewal. This process is controlled by a range of 
transcription factors and initiated by the transcription factor Pax7. Hepatocyte growth 
factor (HGF) initiates activation of quiescent satellite cells, but its downstream effect on 
differentiation is unknown. The activated myoblast will come into contact with 
interstitial extracellular matrix factors such as collagens, fibronectin, decorin and 
laminin. The effect of these ECM factors on C2C12 satellite cell activation and 
differentiation is relatively unknown. By differentiating C2C12 murine myoblasts in 
the presence of various ECM and growth factors we were able to assess the effect that 
these factors had on Pax7 nuclear localization and therefore commitment to 
differentiation. This study shows that collagen I and HGF stimulate the commitment to 
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differentiation of satellite cells via Pax7 activation. Decorin was observed to lower 
average Pax7 levels in the nucleus of proliferating and differentiating myoblasts. The 
addition of decorin is shown to negate the ability for collagen I to increase Pax7 nuclear 
localization. In conclusion, ECM factors have the ability to influence myogenesis. The 
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COLLAGEN IV IS PRO-MYOGENIC AND ALSO REGULATES THE DOSE-
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Extracellular matrix (ECM) and growth factors are known to have complex 
interactions with one another which may modulate their activity in vivo. This supports 
the need to add combinations of ECM and growth factors during in vitro studies to 
more closely mimic in vivo conditions. Murine C2C12 myoblasts were cultured on 
collagen IV in HGF-supplemented media followed by assessment of differentiation and 
proliferation. Collagen IV was not able to negate the negative effect of HGF (2 ng/ml) 
on fusion but was able to restore normal MyHC expression. Collagen IV did not alter 
the pro-myogenic effect of 10 ng/ml HGF. Collagen IV restored normal MyoD 
expression at day 2 of differentiation when cells were exposed to HGF. In proliferative 
conditions, collagen IV alone was unable to effect C2C12 cell numbers, cell viability or 
CD9 expression. Furthermore, collagen IV was observed to be unable to modulate the 
previously reported dose-dependent effects of HGF on C2C12 cell numbers. These 
results show that collagen IV is able to modulate certain aspects of the dual role of HGF 







The South African Society for Biochemistry and Molecular Biology (SASBMB), Cape 
Town, South Africa, 2014 
 
COLLAGEN IV IS PRO-MYOGENIC AND ALSO REGULATES THE DOSE-




School of Life Sciences 
Supervised by Dr Carola Niesler 
 
Extracellular matrix (ECM) and growth factors are known to have complex 
interactions with one another which may modulate their activity in vivo. This supports 
the need to add combinations of ECM and growth factors during in vitro studies to 
more closely mimic in vivo conditions. Murine C2C12 myoblasts were cultured on 
collagen IV in HGF-supplemented media followed by assessment of differentiation and 
proliferation. Collagen IV was not able to negate the negative effect of HGF (2 ng/ml) 
on fusion but was able to restore normal MyHC expression. Collagen IV did not alter 
the pro-myogenic effect of 10 ng/ml HGF. Collagen IV restored normal MyoD 
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Introduction 
Hepatocyte growth factor (HGF) regulates satellite cell activation, proliferation and 
differentiation. HGF transduces its effects on satellite cells through specific interaction with 
the c-Met receptor.   
 
Aim 
We analysed the dose-dependent effects of HGF on C2C12 differentiation, proliferation and 
c-Met expression. We also attempted to understand the mechanisms at play by selectively 
inhibiting pathways downstream from c-Met. 
 
Method 
Murine C2C12 myoblasts were treated with 0, 2 or 10 ng/ml HGF followed by assessment of 
differentiation, proliferation and c-Met expression. Specific inhibitors of PI3K, ERK, JNK 
and p38K were utilized to determine pathway specificity. 
 
Results 
HGF (2 ng/ml) significantly promoted cell division, but reduced myogenic commitment and 
fusion. Conversely, 10 ng/ml HGF reduced proliferative capability, but increased 
differentiation. c-Met expression analysis revealed significantly decreased expression in 
differentiating cells cultured with 2 ng/ml HGF, but increased expression in proliferating 
cells with 10 ng/ml HGF. Mitogen-activated protein kinase (MAPKs: ERK, JNK or p38K) 
and phosphatidylinositol-3-kinase (PI3K) inhibition abrogated the HGF-stimulated increase 
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in cell number. Interestingly, PI3K and p38 kinase facilitated the negative effect of HGF on 
proliferation, while ERK inhibition abrogated the HGF-mediated decrease in differentiation.  
 
Conclusion 
Dose-dependent effects of HGF are mediated by changes in c-Met expression and 





























APPENDIX III: CLUSTAL W (1.81) MULTIPLE SEQUENCE ALIGNMENTS 
 
 
A3.1 Collagen IV (Human vs. Mouse) Score 79.2899 
 
CLUSTAL 2.1 Multiple Sequence Alignments   Sequence type explicitly set to Protein 
Sequence format is Pearson Sequence 1: gi|1674441|gb|AAB19039.1|      1690 aa 
Sequence 2: gi|176866126|ref|NP_444415.2|  1691 aa Start of Pairwise alignments 
Aligning...    Sequences (1:2) Aligned. Score: 79.2899 Guide tree file created:   
[clustalw.dnd]  There are 1 groups Start of Multiple Alignment  Aligning... Group 
1: Sequences:   2      Score:28276 Alignment Score 9044  CLUSTAL-Alignment file 




A3.2 HGF (Human vs. Mouse) Score 89.4882 
 
 
Sequence type explicitly set to Protein Sequence format is Pearson Sequence 1: 
gi|337938|gb|AAA64297.1|   723 aa Sequence 2: gi|632774|gb|AAB31855.1|   728 aa 
Start of Pairwise alignments Aligning...    Sequences (1:2) Aligned. Score: 89.4882 
Guide tree file created:   [clustalw.dnd]  There are 1 groups Start of Multiple 
Alignment  Aligning... Group 1: Sequences:   2      Score:11635 Alignment Score 
4497  CLUSTAL-Alignment file created  [clustalw.aln]   
 
 
A3.3 Laminin 111 vs. Laminin 211 (Mouse) Score 33.8746 
 
CLUSTAL 2.1 Multiple Sequence Alignments   Sequence type explicitly set to Protein 
Sequence format is Pearson Sequence 1: gi|117647249|ref|NP_032507.2|  3118 aa 
Sequence 2: gi|148706391|gb|EDL38338.1|    3079 aa Start of Pairwise alignments 
Aligning...    Sequences (1:2) Aligned. Score: 33.8746 Guide tree file created:   
[clustalw.dnd]  There are 1 groups Start of Multiple Alignment  Aligning... Group 
1: Sequences:   2      Score:24218 Alignment Score 9334  CLUSTAL-Alignment file 





















A4.1 Lysate Preparation 
A4.1.1 Reagents 
Protease Inhibitor Cocktail: The cocktail (Sigma, cat.P8340) consists of the following 
enzymes, AEBSF – [4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride], aprotinin, 
bestatin hydrochloride, E-64-[N-(trans-Epoxysuccinyl)-L-leucine 4-guanidinobutylamide], 
leupeptin hemisulfate salt and pepstatin A. The protease inhibitor was aliquoted into 20 µl 
Eppendorfs and stored at -20 °C. 
 
RIPA Buffer (pH 8): The buffer (Sigma, cat.R0278) contains the following, 50 mM Tris-HCl 
with 150 mM sodium chloride, 1% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate, and 
0.1% sodium dodecyl sulfate (SDS). The buffer was stored at 4 °C. 
A4.1.2 Method 
Cells were collected in a 15ml falcon via trypsinization and spun at 100 x g for 5 minutes on 
the bench top centrifuge (MRC; Polychem Supplies). The supernatant was carefully removed 
leaving the cell pellet behind. The cells were resuspended in 1 ml PBS and spun again at the 
same speed. This washing step was repeated three times. All subsequent steps were 
performed on ice. The cells were resuspended in 24 µl of RIPA buffer and 1 µl Protease 
Inhibitor Cocktail. It must be noted that these amounts are for cells from one well of a 6-well 
plate and must be adjusted to suit cell number. The cells were lysed for 1 hour on ice and 
were then sonicated at setting 13 (VirSonic 60, Polychem Supplies) until all cells were 
ruptured. Finally the samples were transferred into Eppendorfs (10µl aliquots) and stored at -
20 °C.   
A4.2 Bradford Assay 
A4.2.1 Reagents 
Coomassie Dye: 0.12 g Coomassie G-250 (Sigma, cat.B-0770) was dissolved in 5.7 ml 
perchloric acid (2% w/v) and made up to 200 ml with distilled water. The reagents were 
dissolved by stirring with a magnetic stirrer and were filtered through Whatman No.1 filter 
paper. The Coomassie dye was stored in a brown glass bottle at room temperature and kept 
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in the dark for up to 6 months. A calibration curve was created using a bovine serum albumin 
(BSA) stock solution (1 mg/ml) ranging from a 5-50% dilution. 
A4.2.2 Method 
5 µl of sample was added to 95 µl PBS buffer in a 2 ml Eppendorfs (Sigma, cat.T-7813) 
along with 900 µl Coomassie dye solution for 2 minutes. This mixture was then transferred 
to a 1 ml plastic micro-cuvette (Optima Scientific, cat.2711110) and read at A595 on a 
spectrometer (Ultrospec II E, LKB Biochrom). Protein concentrations were calculated from a 
linear equation generated from the calibration curve. All samples were run in triplicate to get 
an accurate assessment of protein concentrations.  
 
Bovine serum albumin standards were used to construct a standard curve (Figure A5.1) as 
described by (Cazzolli et al., 2001). 
 
Figure A4.1: Bovine Serum Albumin (BSA) Bradford standard curve. Bovine serum albumin (BSA, Roche, 
10735086001)) was used to construct a standard curve to determine the unknown concentrations of C2C12 cell 
lysates. BSA protein was made up in d.H20 to a concentration of 1 mg/ml that served as a stock solution. A 
desired range (0 – 40 µg) of protein was added to Bradford reagent (900 µl), made to 1 ml with d.H20 in 
Eppendorfs, vortexed and left to develop for 5 minutes. The protein-dye mixtures were transferred into plastic 
cuvettes and absorbance readings taken at 595 nm with a spectrophotometer. A linear regression formula was 
determined (y = 0.0212x + 0.0172) with a correlation coefficient of 0.99795. The regression formula was used 





Acrylamide/Bis-acrylamide monomer stock solution: 73 g acrylamide (30% m/v) and 2 g bis-
acrylamide (2.67% m/v) were dissolved in 250 ml distilled water. The solution was filtered 
through Whatman No.1 filter paper and stored at 4 °C in a brown glass bottle.  
 
y = 0.0212x + 0.0172 


















4 x running gel buffer (1.5M Tris-HCl, pH 8.8): 72.72 g Tris was dissolved in 400 ml 
distilled water. The pH was titrated to pH 8.8 with HCl. The solution was filtered through 
Whatman No.1 filter paper and stored at 4 °C in a glass bottle.   
 
4 x stacking gel buffer (500mM Tris-HCl, pH 6.8): 3 g Tris was dissolved in 50 ml distilled 
water. The pH was titrated to pH 6.8 with HCl. This solutions pH should be checked weekly. 
The solution was stored in a glass bottle at 4 °C. 
 
SDS stock solution: 5 g SDS (10% m/v) was dissolved in 50 ml distilled water. The solution 
was filtered through Whatman No.1 filter paper and stored in a glass bottle at room 
temperature. 
 
Ammonium persulfate initiator solution: 0.1 g ammonium persulfate (10% m/v) was 
dissolved in 1 ml distilled water. This reagent was made up fresh prior to use. 
 
2X Reducing sample treatment buffer (125mM Tris-HCl, pH 6.8): 2.5 ml of the 4x stacking 
gel buffer, 4 ml SDS stock solution, 2 ml glycerol, and 1 ml of 2-mercaptoethanol were 
made up to 10 ml with distilled water and titrated to pH 6.8. The solution was stored in a 
sealed container at room temperature.  
 
Electrode (tank) buffer (250mM Tris-HCl, pH 8.3): 0.75 g Tris, 3.6 g glycine, and 2.5 ml 
SDS stock solution were made up to 250 ml distilled water and titrated to pH 8.3. The 
solution was stored in a plastic container at 4 °C. 
 
Coomassie G-250 stain: 0.2 g Coomassie G-250, 24 ml phosphoric acid, 50 g aluminum 
sulfate, 100 ml ethanol were made up to 1 liter with distilled water. The solution was filtered 








Table A4.3.1. Preparation of 10% and 12.5% Laemmli running and stacking gels for SDS-PAGE  
Reagents 10% 12.5% Stacking Gel 
Monomer Solution 5 ml 6.25 ml 0.94 ml 
4x Running Gel Buffer 3.75 ml 3.75 ml - 
4x Stacking Gel Buffer - - 1.75 ml 
Distilled Water 6 ml 4.75 ml 4.3 ml 
SDS Stock Solution 150 µl 150 µl 70 µl 
Initiator Solution 75 µl 75 µl 35 µl 





























APPENDIX V: WESTERN BLOT AND DOT BLOT 
 
 
A5.1 Western Blot 
A5.1.1 Reagents 
 
Blotting buffer: 27.23 g Tris and 64.8 g glycine were dissolved in 3.5 liters distilled water, 
followed by the addition of 900ml methanol. The solution was then made up to a final 
volume of 4.5 liters with distilled water. Prior to use 10% (m/v) SDS was added to the 
solution (i.e. 4.5 ml in 450 ml). Blotting buffer was used for 3 blotting runs before fresh 
blotting buffer was made again. Blotting buffer was stored in the fridge (4°C). 
 
Tris buffer saline-Tween (TBST; 20mM Tris, 200mM NaCl, pH 7.4): 2.42g Tris and 11.69 g 
NaCl were dissolved in 950 ml distilled water. The pH was titrated to pH 7.4 with HCl and 
subsequently made up to 1 liter with distilled water. Finally, 500 µl Tween-20 (Sigma, 
cat.P1379) was added to the solution that was stored in the fridge (4 °C). 
 
Ponceau S. stain: 0.1g Ponceau S. (Fluka, cat.81460) was dissolved in 1 ml acetic acid 
(100%) and made up to a final volume of 100 ml with distilled water. The solution was 
stored in a plastic bottle at room temperature. 
 
A5.2 Dot Blot 
Dot blot analysis was used to determine the optimal dilution of the primary and secondary 
antibodies for western blot analysis. A piece of nitrocellulose was marked into a grid with a 
pencil (Refer to figure 3.3). Note: gloves were worn at all times when dealing with protein 
samples. 1 µl of a protein sample was spotted into each square marked out on the 
nitrocellulose. The whole nitrocellulose piece was then blocked for 30 minutes, with 5% 
(m/v) non-fat milk powder made up in TBST. The nitrocellulose was cut into the marked 
squares that had been labeled with a predetermined antibody dilution range. Each antibody 
will have its own unique dilution range determined from the literature. Each square was 
placed into a separate well of a 12-well plate. The primary antibody dilutions were made up 
in TBST, and 500 µl of the specific dilution was added to each well for 2 hours. This was 
followed by washing steps with TBST (3 x 5 minutes). Secondary antibody dilutions were 
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made up in TBST and added to the well (500 µl) for 1 hour. The wells were then washed 
again with TBST (4 x 5 minutes). ECL was performed on the nitrocellulose squares. The 
dilution range showing optimal binding of both primary and secondary antibodies without 
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